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The complementary and alternative medicines (CAM) industry is worth over US$110 billion 
globally. Products are available to consumers with little medical advice; with many assuming 
that such products are ‘natural’ and therefore safe. However, with adulterated, contaminated 
and fraudulent products reported on overseas markets, consumers may be placing their 
health at risk. Previous studies into product content have reported undeclared plant 
materials, ingredient substitution, adulteration and contamination. However, no large-scale, 
independent audit of CAM has been undertaken to demonstrate these problems in Australia.  
This study aimed to investigate the content and quality of CAM products on the Australian 
market. 135 products were analysed using a combination of next-generation DNA sequencing 
and liquid chromatography-mass spectrometry. Nearly 50% of products tested had 
contamination issues, in terms of DNA, chemical composition or both. 5% of the samples 
contained undeclared pharmaceuticals. 
Increasing reports of adulteration with novel drug analogues led to the development of a 
high-throughput untargeted method for pharmacovigilance. Rapid direct sample analysis 
coupled to mass spectrometry was used to screen products, this time for hundreds of 
compounds in minutes with minimal sample preparation. The data correlated well with 
previous analyses, with the added benefit of detected additional compounds including 
phytochemicals and vitamins.  
Finally, metabolomics was used to assess the compositional diversity of finished herbal 
products on the market and how they compare to standard reference materials. The analysis 
iii 
 
showed that, despite all products stating the same ingredients, there was a clear difference 
in biochemical profile between products and also the reference materials.  
The combined techniques and analyses used in this project provide an audit and quality 
control toolkit which will allow for stronger regulation of CAM products. The data collected 
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1. Background to the regulation, safety and quality control of 
complementary and alternative medicines 
 
This thesis explores the composition, safety and quality of complementary and alternative 
medicines (CAM) on the Australian market from 2014 to 2017. CAM can be defined as any 
treatment, product, drug or supplement which is used in combination with, or in place of, 
conventional medicine and is not considered to be a part of an evidence-based medicinal 
treatment 1. The use of CAM products has grown substantially in the last two decades 2-5, with 
a global market valued at US$83 billion per year in 2010 6, to now being estimated at over 
US$150 billion by 2025 7. The market is only expected to grow. The topic of CAM is 
controversial for several reasons. Ongoing questions about the effectiveness of treatments 
using herbal medicines, homoeopathy, naturopathy and traditional medicines ignite strong 
debate from both supporters of CAM and advocates of evidence-based medicines. Debate 
continues on topics including the use of funding, appropriateness of scientific methods, 
ethical considerations and conflicts of interest, bias in data and interpretation and the overall 
scientific consensus. Controversy also exists as to the best way to approach CAM use and 
demand in patients and general consumers, the possible benefits and risks of ‘integrative’ 
medicines 8, the advertisement of CAM products to consumers and the claims of benefit and 
efficacy of CAM, often without strong scientific evidence. This thesis does not directly address 
these topics (indeed, the above-mentioned areas would fill many books 9-12), and nor does it 
discuss the potential efficacy of CAM products. Instead, I argue that discussions regarding 
efficacy should be surpassed by urgent issues of safety and quality.  
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Key to any discussion of CAM safety are matters regarding regulation and the debate over 
how much ‘red tape’ is needed to ensure consumer safety, without unnecessarily impeding 
consumer access to CAM products. This subject of regulation is, therefore at the heart of this 
thesis. In the debate about efficacy, demand, acceptance and integration of CAM into 
mainstream medicine, potential issues of quality and safety are often overlooked. It is only 
due to the substantial increase in use that attention has been drawn to the regulation and 
safety of CAM, in particular to the safety of herbal medicines and dietary supplements, their 
side effects and possible interactions with conventional medication. These products are 
already on the market and are being regularly taken by over 50% of the population 13. In many 
countries, regulation of CAM is relatively lax, due to a perception of lower risk compared to 
prescription and over-the-counter drugs. In Australia, the Therapeutic Goods Administration 
(TGA) is the regulatory body for medicines and medical devices, with products requiring an 
entry in the Australian Register of Therapeutic Goods (ARTG). Under this system, CAM 
products are ‘listed medicines’ (AUST L) and post-market monitoring is generally less rigorous 
than registered medicines (AUST R), such as prescription drugs, which are considered high-
risk and whose efficacy must be demonstrated along with safety and quality 6,14. The unique 
AUST L number for each CAM remedy must be displayed on the packet as part of the 
regulation for therapeutic products. The number denotes that the CAM remedy is considered 
‘low risk’, and that the product is manufactured in accordance with Good Manufacturing 
Practices (GMP) and complies with safety and quality criteria. An AUST L number does not 
permit any therapeutic claims for the indications of use 6. In spite of this system, there is a 
perception within the general public that CAM remedies have been tested for efficacy, safety 
and quality before going onto the market 15. The ideal of ‘natural’ CAM products equating to 
safe products is not only wrong; it is a key belief and explanation for the vast industry growth 
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16,17. Issues with adulterated, contaminated and mislabelled products further complicate the 
problem with the increased use of CAM. The presence of these adulterants and contaminants 
may not be immediately known to treating doctors and other healthcare workers; leading to 
delays in diagnosis or even misdiagnosis 18. 
Outline of Thesis 
This project on CAM products on the Australian market is part of a larger study, in which we 
have sought to answer the question posed by Byard, et al. 19: “What are the risks to the 
Australian community from herbal medicines?”. This project follows on from a preliminary 
study in 2013 (paper in Appendix) which found that 92% of the products tested had some 
form of contamination, adulteration and/or substitution 20. In particular, this thesis explores 
the use of advanced mass spectrometry to investigate the composition of CAM products and 
better understand the safety implications of these products. The thesis is in two parts; a) a 
selective look at the risk of adulteration, followed by b) a wider focus on the overall 
composition of CAM products.  
Part A concerns the screening and detection of possible adulterated and contaminated CAM 
products, with the aim of developing new methods by which this could be achieved. Part A 
starts with a review of published methods for adulterant detection in CAM products, with an 
emphasis on how adulterated products are a clinically relevant problem (Chapter 1). Chapter 
2 is the first experimental section focusing on “Toxicological screening and DNA sequencing 
detects contamination and adulteration in regulated herbal medicines and supplements for 
diet, weight loss and cardiovascular health” 21.  Following on from the data in Chapter 2, 
Chapters 3 and 4 detail the development and application of a screening method utilising a 
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new direct mass spectrometry platform and the application of that method for the rapid 
analysis of CAM products.  
Part B focuses on the overall composition of herbal CAM products and advocates for the use 
of a metabolomic approach to assess quality and safety. Part B starts with Chapter 5, an essay 
on the potential application of metabolomics for herbal medicine pharmacovigilance. Chapter 
6 uses a metabolomic approach to assess the compositional similarities of commercial herbal 
products (green tea and Korean ginseng).   
Significance, rationale and research questions 
No large-scale, independent audit of CAM has been undertaken in Australia. This means that 
there is no clear picture of whether the widespread problems of adulteration, contamination 
and mislabelling that are seen overseas are present in Australia. To gain a true picture of the 
extent of the problem and therefore the risk to consumers, a large-scale screen of CAM 
products available in Australia must be undertaken, which is what this the first half of this 
project aimed to do. There is also a gap in the literature in regard to fast, high-throughput 
screening methods which could be adapted to commercial use and also pre- and post-market 
audits and reviews for regulatory bodies. All of this led to the research question for part A: 
What is the occurrence of adulteration/contamination in CAM products available in 
Australia? 
The second aim of this project was to assess the compositional diversity among CAM products 
on the market. As the results for part A show, product labels are often inaccurate at best, 
leaving us to wonder just what is in the products tested. By using metabolomics, we can 
investigate the quality differences in CAM products as well as safety. For example, are all 
green tea products the same? Metabolomics is the identification and quantification of the 
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small molecules within a biological system under specific conditions. As reviewed in Chapter 
5, metabolomics can provide detailed insights, or ‘snapshots’ of the effect of environmental, 
genetic and processing factors on herbal medicines. The application of untargeted methods 
such as metabolomics and metabolite profiling provides yet another set of methods for 
quality control and pharmacovigilance of formulated products. This led to the part B question:  
What is the compositional diversity /similarity of formulated herbal products? 
The potential risk to consumers in Australia from CAM is currently ill-defined. It appears from 
the preliminary study 20 and a review of the literature that current regulation is failing to 
ensure the safety and quality of CAM products on the Australian and overseas markets, and 
that the potential risks from CAM, notably herbal medicines, may outweigh any benefits of 
use. There is also clear economic motivation to ‘improve’ products with the use of undisclosed 
ingredients 22. With the questions outlined above, the overall aim of this thesis was to answer 
the following questions: 
What is in these herbal products and does the content match the label? 
What is the risk posed to consumers by CAM products? 
The data from this project will give weight to the arguments on whether Australia (and other 
countries) need stronger CAM regulations, guide future research into CAM products and 
herbal medicine composition and develop and apply an audit and quality control method 
toolkit. 
Definitions of common terms 
The following terms have been used throughout the thesis. Below outlines the definition and 
criteria as to when this nomenclature is used. In some cases, it is not possible to distinguish 
between adulteration, contamination, or ingredient substitution. 
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Adulteration: The addition of an undeclared substance to a product. For example, when a 
pharmaceutical detected cannot be explained by the products ingredients list, it is possibly 
adulterated. 
Contamination: The inadvertent addition of a substance to a product. For example, when 
DNA from plants or animals not listed o related to ingredients is found. Pharmaceutical and 
heavy metal contamination is also possible. 
Substitution: Where an ingredient listed on the package has instead been switched for  
possibly cheaper material 23.  
Undeclared ingredients: An umbrella term for substituted ingredients, adulterants and/or 
contaminants. 
Note to the reader 
Certain details such as industry worth, product usage, etc. vary from chapter to chapter based 
on the information that was available at the time of publication, with the most recent figures 
quoted in the main introduction.  
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Contamination, adulteration and toxicity concerns with Complementary and 
Alternative medicines.  
 
Abstract 
Complementary and alternative medicines (CAM) are becoming more popular choices for 
consumers worldwide, and are utilised for a broad range of diseases. Consumer use is 
generally in a ‘self-treatment’ manner, with such products assumed to be ‘natural’ and 
therefore safe. However, light regulation and these wrongful assumptions of safety have led 
to alarming outcomes and adverse effects for consumers, with numerous case studies 
demonstrating how adulterated products have led to overdose or poisoning. Adulterated and 
contaminated CAM products are known problems for quality control and pharmacovigilance. 
Pharmaceutical adulterants are generally found in herbal medicines that have matching 
indications. However, this is not always the case and screening methods, therefore, need to 
be able to detect both expected and unexpected compounds for pharmacovigilance 
purposes. A range of mass spectrometry-based methods for adulterant detection in CAM 
products have been developed to help ensure safety and quality and for continued 
pharmacovigilance. Such methods must be rapid and high-throughput if they are to be 
adapted for regulatory use, with LC-MS/MS methods being the preferred choice due to the 
sensitivity and range of application to pharmaceuticals. New, un-targeted screening methods 
have a strong potential for detecting drug analogues and novel compounds. This would allow 
for more effective regulation, the establishment of more rigorous standardised methods and 
the reduction of adverse health outcomes for consumers. While under-reported, adulterated 
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products are a clinically relevant problem for consumers, with adverse effects ranging from 
headaches and rashes to cognitive impairment and death. 
 
Introduction 
Complementary and alternative medicines (CAM) can be defined as ‘procedures and products 
excluded from mainstream medicine’ 1, and commonly include traditional medicines, herbal 
medicines and homoeopathic remedies. Natural health products such as vitamins and 
supplements are also included under the umbrella of CAM. Recently, there has been a marked 
increase in the use of CAM, with products typically used in self-treatment and self-selected 
manner by consumers, often seen as ‘low risk’ 6. Associated with this increase in use, there 
has been an increase in concern about the safety and quality of CAM products in the 
literature, as reviewed below. With the regulation of CAM often ‘soft-touch’ and industry-
based 6, adulterated and contaminated products can more easily make their way onto the 
market and to consumers. This has resulted in overdoses 24,25, adverse effects from 
pharmaceuticals which the patient was unaware they were even taking 26,27 and poisoning 
from contaminants such as heavy metals 28.    
There have been many reports on the adulteration and contamination of herbal medicines, 
and several extensive reviews on the subject 2,29. However, with regard to the regulatory 
control of CAM, safety issues are often insufficient, and with the increasing use of CAM, there 
is pressure for such issues to be addressed 19,30. Cases of adulteration can sometimes be seen 
as economically motivated fraud, which arises for financial advantage 31. This leads to a clear 
conflict of interest between compliance and financial gain in the largely industry-based 
regulatory system, leaving some companies with little motivation to follow regulations, both 
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in Australian and internationally 32. An excellent example of conflict of interest is given by Li, 
et al. 8 on the inclusion CAM at medical institutions in the USA due to the financial incentives 
but without providing evidence-based care. In some countries, such as Australia, there is also 
a lack of enforcement in cases of non-compliance 33. A comprehensive summary of the 
literature on the adulteration and contamination of herbal medicinal products can be found 
in Posadzki, et al. 29, and the need for better regulation of CAM has been strongly emphasised 
by Ernst 2. The regulations in Australia, New Zealand, the USA and Canada have been 
summarised by Barnes, et al. 34 and Job, et al. 35. 
The purpose of this review is to support the argument for stronger regulation and 
pharmacovigilance of CAM products by highlighting clinically relevant outcomes of 
adulteration and contamination. Additionally, a summary of recently published methods for 
the screening of CAM is included to demonstrate that relevant screening and detection 
methods have been developed and are already available for regulatory use.  
Adulteration screening studies and mass spectral analysis 
Adulteration of herbal medicines with pharmaceuticals is not a recent problem. In 1997, 
Huang, et al. 36 found that nearly 24% of traditional Chinese medicines (TCM) in Taiwan were 
adulterated with pharmaceuticals. Since then there have been numerous reports of 
pharmaceutical adulteration of herbal medicines, summarised in Table 1-1. The literature 
presented in Table 1-1 shows that herbal products for male health and sexual function, along 
with slimming products and remedies for general health are often adulterated with 
pharmaceuticals that suit their intended purpose and indications for use. This problem can 
be addressed using targeted screening of known or likely adulterants for certain indications 
or specific cases. Adulterants are generally found in herbal medicines with indications 
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matching the therapeutic class of the pharmaceutical 36,37, although in some instances there 
appears to be no logical reason for the adulteration 36,38. This is demonstrated by Poon, et al. 
38, where the addition of glibenclamide would have had no effect on the indication for ‘sexual 
enhancement’.  
This ‘adulterant to match indication’ also highlights a possible bias in adulteration studies, 
due to the selection of samples for analysis, as well as the range of potential pharmaceutical 
adulterants screened. Many of the studies presented in Table 1-1 considered only a specific 
set of products, such as those indicated to ‘enhance sexual performance’ 39,40. There were 
also methods developed to detect only certain classes of pharmaceutical, such as those by 
Savaliya, et al. 41 and Kim, et al. 42,43. The studies by Bogusz, et al. 44, Wang, et al. 45 and Huang, 
et al. 36, where upwards of 60 drugs were screened in each study, give a much broader view 
of the magnitude of the adulteration problem. 
A number of techniques have been used for the detection of undisclosed pharmaceuticals in 
herbal medicines, including high performance liquid chromatography (HPLC) 40,46-48, nuclear 
magnetic resonance (NMR) spectroscopy 49,50, direct mass spectrometry (MS) 51-54 and various 
hyphenated methods such as gas chromatography-mass spectrometry (GC-MS) 46, liquid 
chromatography-mass spectrometry (LC-MS) 40 and liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) 44,48,55,56. Haneef, et al. 57 and Vaclavik, et al. 58 discuss the various 
methods used for adulteration studies in great detail. LC-MS/MS is arguably the most popular 
technique, as it is applicable to a wide range of pharmaceuticals 59, as well as being sensitive, 
quantitative, highly selective and usually requires only simple sample preparation 57. In 
addition, the MS fragmentation patterns give structural information, allowing for the 
identification of unknown analytes. Table 1-2 summarises LC-MS methods that have been 
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used in screening studies for adulterants in herbal medicines since 2000. The majority of the 
methods were quantitative and used only a simple solvent extraction with sonication and 
filtration before instrumental analysis. For a method to be easily adopted for regulatory 
purposes, it needs to be rapid, simple and preferably cheap. 
Not all adulterants are approved pharmaceuticals, as analogues and new compounds have 
also been detected in CAM products (see Table 1-1 and Table 1-3). Two studies by Cohen, et 
al. 60,61 found analogues of methamphetamine and the stimulant 1,3-dimethylamylamine 
(DMAA) in workout supplements. After several athletes failed drug tests due to a positive 
result from the methamphetamine analogue N,α-diethyl-phenylethylamine (N,α-DEPEA), 
their workout supplement was investigated as the possible source. Three samples of the 
supplement from different batches were tested, and in each case, N,α-DEPEA was detected. 
N,α-DEPEA is a known stimulant, but its addictiveness and possible adverse effects are 
unknown 60. In the other case, an analogue of DMAA, 1,3-dimethylbutylamine (DMBA) was 
found in 12 out of 14 supplements tested. This is highly concerning as DMBA has never been 
tested in humans and has no safety profile, while DMAA is banned in many countries due to 
possible serious health risks including stroke and heart failure 61. The majority of the methods 
in Table 1-1 and Table 1-2 did not include analogues amongst their targets; those included 
were mostly known PDE-5 inhibitor analogues. Only Wang, et al. 45 actively looked for 
unknown adulterants using a HPLC-HRMS method. The detection of such novel compounds 
would remain a challenge even with the more comprehensive methods listed. 
More studies are needed that screen for diverse products and indications, as well as the use 
of untargeted methods which profile hundreds of pharmaceuticals and other potentially 
problematic compounds 45. These are particularly important for cases where a product has 
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been adulterated with an unexpected drug that has no obvious benefit for the product 
indications. This type of approach creates a clear distinction between non-quantitative 
screening for the presence of pharmaceuticals and quantification of any adulterants found. 
An ideal approach would be an initial screen using an untargeted method, followed by 
confirmation and quantification with a targeted method. Screening has the benefit of being a 
rapid process by which hundreds of samples can be tested in the minimum time, where a 
quantitative method is not necessary. If a positive sample is detected, confirmation and 
quantification against reference standards can follow, but only for those positive samples. A 
two-step process would ensure a high throughput of samples without unnecessary 
quantification and confirmation for negative samples. There is a potential for other MS 
platforms, such as direct MS, to be implemented for a two-step process 51-54. These screening 
approaches need to be implemented on an ongoing basis, as batch-to-batch variation means 
that while one batch may be safe and free of possible adulterants, the next batch may not 62. 
Clinical relevance and case studies   
The clinical relevance of adulterated products can be hard to define. This is often due to the 
fact that use of herbal medicines is not reported to a patient’s general practitioner or 
pharmacist, providing little or no record of product use 18,63,64. One case study 63 reported a 
patient who was taking 24 CAM remedies along with one prescription medication. While 
there was no adverse outcome, the total number of individual ingredients from the 24 
different remedies was greater than 55, and these remedies were taken without any 
disclosure to the patient’s general practitioner or pharmacist. 
A second factor is that any side effects from the product or the adulterant might not be 
associated with the herbal medicine due to the preconceived idea that herbal medicines are 
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‘natural’ and harmless, and therefore could not cause side effects 26,64-66. Effective systems 
for reporting such side effects and adverse reactions are generally not in place, hindering the 
collection of data and, even with such systems, consumers may not report side effects from 
CAM products 64,66-68. These limitations are often noted in case studies or reports, and there 
is an assumption that the incidence of side effects and adverse reactions is repeatedly 
underestimated 2,26,67,68. Yet it is clear from the below studies (Table 1-1 and Table 1-2) that 
consumers are being exposed to adulterated products. Many of the detected pharmaceuticals 
in Table 1-1 are common, well-tolerated drugs, such as paracetamol, sildenafil and caffeine, 
raising the possibility the adulterant’s therapeutic actions are being attributed to the efficacy 
of the CAM product, resulting in the adulterated products not being reported 20. 
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Table 1-1: Summary of adulteration studies from 1997 to 2015. Literature search terms included herbal medicines, traditional Chines medicines, 
Complementary and alternative medicines, adulteration and contamination. NSAIDs= Nonsteroidal anti-inflammatory drugs, PDE5= 
phosphodiesterase type 5. 
Author Samples Indications Results Comments 
Bogusz, et al. (2006)  
Various herbal 
remedies and products 
Various, including male 
sexual function, 
slimming remedies, 
natural general health 
and diabetes. 
Sildenafil, tadaladil, glibenclamide, 
fenfluramine, phentermine, 
caffeine, phenylbutazone, 
dipyrone and testosterone 
decanote. 
80 drugs from various 
classes were screened in 
this method. 
Campbell, et al. 
(2013) 39 
91 samples of herbal 
products were 
collected from 
locations in Atlanta and 
Baltimore, USA. 7 
samples were from the 
USA. Customs seizures. 
There were 58 
different products.                                                                                                                                                                                   
Naturally enhance 
sexual performance. 
81% of the samples contained one 
or more PDE5 inhibitor (tadalafil 
and sildenafil) or an analogue of a 
PDE5 inhibitor. 
14 samples warned against 
the concurrent use with 
nitrates. 18 of the 40 
samples that contained a 
PDE5 inhibitor had a 
contraction of a greater 




Author Samples Indications Results Comments 
Cho, et al. (2014) 55 
294 food and dietary 
supplements collected 
over 4 years in South 
Korea. 
Arthritis, bone ache 
and joint pain. 
Around 30% of the samples were 
positive for steroids. 45.1% of the 
positive samples contained 
dexamethasone. 
35 different steroid 





cortisone and derivatives. 
Gratz, et al. (2004) 40 




19 of the products contained 
therapeutic levels of a PDE5 
inhibitor.  
Only sildenafil and tadalafil 
were detected, not 
vardenafil. 
Huang, et al. (1997) 
36 
Over a year, 2609 
samples of traditional 
Chines medicines were 
collected from 





were the most frequently 
detected. 
618 samples (23.7%) had 
been adulterated with 69 
different substances 
Kim, et al. (2014) 42 
188 food and dietary 
supplements from 
South Korea collected 







sennoside A, sennoside B and 
sibutramine were detected in 62 
samples. 





Author Samples Indications Results Comments 
Kim, et al. (2014) 43 
126 food and 88 
dietary supplements 
from South Korea (total 
= 214). 
Not given. 
52 samples were adulterated with 
paracetamol, diclofenac, 
ibuprofen, indomethacin, 
naproxen and piroxicam. 
Samples were screened for 
paracetamol and 16 
NSAIDs. 
Ko (1998) 62 
260 Asian patent 
medicines from retail 
herbal stores in 
California, U.S.A. 
Not given. 
At least 83 products contained 
undeclared pharmaceuticals or 
heavy metals. 23 products had 
more than one adulterant. Most 




14 products were labelled 
declaring pharmaceuticals. 
Authors noted that due to 
batch to batch 
inconsistency the remaining 
products could not be 
assumed to be safe. 
Li, et al. (2010) 56 




14 samples were positive for 9 
different adulterants, including 
chlorpropamide, glenclamide, 
gliclazide, glimepiride, metformin, 
mitiglinide, nateglinide, 
phenformin and rosiglitazone.  
Method was to identify 14 
anti-diabetic drugs. 
Lau, et al. (2003) 69 
Indonesian sachet of 
powdered herbs. The 
product had been 
recalled and banned in 
Singapore in 2002. 
Rheumatism, body and 
bone aches, muscle 
and joint pain, 
giddiness, toothache, 
backache and chronic 
numbness 
Caffeine, phenylbutazone and 
oxyphenbutazone  
The doses of caffeine and 
phenylbutazone were 
below the daily therapeutic 
dose if the remedy was 
taken as recommended. 
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Author Samples Indications Results Comments 
Liang, et al. (2006) 37 
Over 200 products 
were analysed after 
being confiscated by 
the State Drug 
Administration (SDA) of 
China.   
Not given 
74 products were positive for 
sildenafil, famotidine, ibuprofen, 
promethazine, diazepam, 
nifedipine, captopril, amoxicillin 
and dextromethorphan.  
Sildenadil and famotidine 
were the two most 
commonly detected 
pharmaceuticals. 




Small amounts of codeine were 
detected (61.8 µg/capsule) 
 
Miller and Stripp 
(2007) 46 
90 Chinese herbal 













diphenhydramine and sildenafil. 
 
Panusa, et al. (2007) 
48 
Homeopathic products For inflammation. 
None of the products were 




and piroxicam were 




Author Samples Indications Results Comments 
Reeuwijk, et al. 
(2014) 27 
50 herbal food 
supplements sold on 
the Dutch market 
between 2004 and 
2013.  
Weight loss. 




phenolphthalein, sildenafil and 
rimonabant) with 11 samples 
having more than one adulterant. 
Sibutramine was the most 
commonly detected. 
Ren, et al. (2012) 70 
16 herbal medicines 
from markets and the 
internet. 
Male sexual potency. 
9 samples contained PDE5 
inhibitor and/or an analogue. 
Method was designed to 
screen for yohimibine and 
PDE5 inhibitors and 
analogues. 
Savaliya, et al. (2009) 
41 
58 Ayurvedic herbal 
medicines where 
purchased in India. 
Not given. 
12 samples were positive for 
dexamethasone, diclofenac and/or 
piroxicam. 
Method was developed to 
detect steroidal and NSAIDs 
adulteration. 
Wang, et al. (2008) 71 
Around 50 samples of 
health food and herbal 
medicines from local 
Chinese suppliers or 
the internet. 
Various. 







Table 1-2: Summary of the methods used in analytical adulteration studies. ACN = Acetonitrile, DAD = Diode-array detector, ESI = Electrospray 
ionization, EtOH = Ethanol, HRMS = High resolution mass spectrometry, MeOH = Methanol, MRM = Multiple reactions monitoring, MTSF = Mass 
spectral tree similarity filter, SRM = Selected reaction monitoring, TLC = Thin-layer chromatography, TOF = Time of fight, UFLC = Ultra-fast liquid 
chromatography, UHPLC = Ultrahigh-performance liquid chromatography, UPLC = Ultra-performance liquid chromatography. 
Author Sample Matrix Extraction Instrumentation  Quantitative 
Bogusz, et al. 
(2006)  
Herbal remedies, 
ground to a 
homogenous material 
Extracted with MeOH for 30min. Samples with 
sugar (e.g. honey) were extracted with 
dichlormethane-isopropanol (9:1) and then 
evaporated with N2 and reconstituted with 
MeOH. 
LC-ESI-MS/MS in MRM Yes 
Cho, et al. (2014) 55 
Samples were classes as 
liquid, powder, pill, 
tablet, capsule or 
granules. 
Dissolved in 70% MeOH and sonicated for 30 
min. Filtered before analysis. 
LC-ESI-MS/MS Yes 




Extracted with 50/50 ACN and water and then 
sonicated for 15 min. Filtered and diluted with 




Guo, et al. (2014) 72 
Herbal medicines and 
dietary supplement in 
the form of tablets, 
pellets or capsules. 
Samples pulverised to a homogeneous powder. 
ACN and water (v/v 60:40) was added and the 
samples were shaken for 30 secs and sonicated 
for 15 min at 20°C and then diluted with ACN 
and water. Extracts were left to stand for 10 min 






Author Sample Matrix Extraction Instrumentation  Quantitative 
Kim, et al. (2014) 43 
Various forms; powder, 
capsules, pills, tablets, 
granules. 
Extracted with 70% MeOH and sonicated for 
30min. Filtered before analysis. 
LC-ESI-MS/MS Yes 
Lau, et al. (2003) 69 Powdered herbal sachet 
EtOH was added to the sample and then boiled 
and filtered. Extraction was repeated 3 times. 
The extract was evaporated and reconstituted in 
MeOH. 
LC-MS/MS in SRM. Yes 
Li, et al. (2010) 56 
Chinese medicines in 
the form of tablets, 
pills, granules and 
capsules. 
Samples grounded to a homogeneous powder, 
extracted in MeOH and sonicated for 20 min 
UPLC-MS/MS Yes 
Liang, et al. (2006) 
37 
Products were mostly in 
capsule, tablet or oral 
solution form 
Mobile phase was added to the samples and 
then extracted in an ultrasonic washer. Samples 
were centrifuged and supernatant was diluted 
for analyses.  
LC-MS/MS in MRM No 
Liu, et al. (2000) 47 
Herbal capsules, with 
between 9 to 11 
ingredients. Tested for 
the presence of 
codeine.  
Capsules dissolved in 10mM sodium phosphate 
buffer and EtOH. The mixture was then 
extracted using chloroform and evaporated. 











Author Sample Matrix Extraction Instrumentation  Quantitative 
Lu, et al. (2010) 73 
35 samples of dietary 
supplements and 
traditional Chinese 
medicines in the forms 
of either capsules or 
tablets. 
Samples ‘smashed’ and mixed homogeneously. 
Extracted with MeOh-water (v/v 1:1) by 
sonication for 30 min. 
HPLC-ESI-MS/MS Yes 
Miller and Stripp 
(2007) 46 
Chinese herbal 
medicines in various 
forms; pills, teas, 
capsule, creams, etc. 
Pills, tablets and capsules were ground and 
extracted with MeOH. Samples were then 
vortexed, centrifuged and filtered. 
Teas were brewed according to packaging 
instructions. Samples were then centrifuged and 
filtered. 
Creams were dissolved in methylene chloride, 
vortexed and then centrifuged and filtered. 
All samples were then adjusted to an acidic (pH2 




in SIM and HPLC 
No 
Panusa, et al. 
(2007) 48 
Homeopathic products 





All samples were diluted with MeOH-water (v/v 
80:20), spiked, homogenised, sonicated and 
then filtered before analysis. 
HPLC-UV 




Author Sample Matrix Extraction Instrumentation  Quantitative 
Reeuwijk, et al. 
(2014) 27 
Herbal supplements, 
mostly in the forms of 
capsules, tablets and 
sachets 
The samples were sonicated with MeOH, and 
then diluted 100 fold with MeOH/0.1% formic 
acid. Extracts where filtered before analysis. 
HPLC-DAD-MS/MS Yes 
Ren, et al. (2012) 70 
Herbal medicines in the 
forms of capsules or 
tablets 
Samples ground to a homogeneous powder. 
MeOH was added and samples were extracted 
by vortexing and sonication. The extracts were 
diluted before analysis. 
UFLC-ESI-MS/MS Yes 
Savaliya, et al. 
(2009) 41 
Ayurvedc herbal 
medicines from India 
Samples extracted with 80% MeOH, sonicated 
and centrifuged. 
LC-MS/TOF using both 
APCI and ESI. 
Yes 
Wang, et al. (2008) 
71 
Health foods and herbal 
medicines in tablet or 
capsule forms. 
Samples homogenised, sonticated for 15 min 
with MeOH. Extract was centrifuged and 
supernatant diluted with MeOH.  
HPLC-HRMS with data 




Table 1-3: Summary of case studies concerning adverse effects from adulterated products. 
Author Product used Adulterant/ Contaminant Adverse Effects Comments 
Amster, et al. 
(2007) 28 
Kelp Supplement Arsenic (8.5 mg/kg) 
Alopecia, memory loss, 
diarrhoea, nausea, 
vomiting, weakness, 
fatigue, headache and rash. 
The patient had originally 
increased the dose of the 
supplement to help treat 
her alopecia and memory 
loss. Occurred in California, 
USA. 
Chen, et al. (2010) 
65 





and Fenfluramine.  
Psychotic features included 
auditory and (63%) visual 
hallucinations (38%), 
persecutory ideas (38%), 
delusive thoughts (25%) 
and suicidal ideation (13%). 
14 of the products 
contained more than one 
adulterant. 
The amount of sibutramine 
was determined for some 
of the products with a 
range from 2.8 to 19.6 mg. 
Cases occurred in Hong 
Kong, with products 
purchased locally, over the 
internet, and overseas. 
Corns and 
Metcalfe (2002) 15 




Hypertension, weight loss, 
abdominal pain, nausea, 
visual hallucinations. 
Occurred in the UK. Three 
cases of patients taking 
various herbal weight loss 




Author Product used Adulterant/ Contaminant Adverse Effects Comments 
Jung, et al. (2006) 
24 
Chinese herbal medicine for 
weight reduction 
Sibutramine 
Headache, vertigo and 
numbness 
One capsule contained 27.4 
mg of sibutramine; 
approximately double the 
highest single dose (12.55 
mg). Occurred in Germany 
with the product purchased 
over the internet. 
Lim, et al. (2011) 
26 
Multiple ingredient herbal 
product 
Steroids Not detailed. 
Product consumed by a 
child (age between 0 to 16 
yrs.) Occurred in Australia. 
Poon, et al. (2009) 
38 
Numerous (n= 25) erectile 
dysfunction products  







Occurred in Hong Kong, 
products coursed from 
various places including 
pharmacies in Hong Kong 
and China. 
Tait, et al. (2002) 
74 
Ayurvedic tablets Lead and mercury 
Chronic lead poisoning of a 
preterm infant via mother. 
The mother’s intake of lead 
was greater 50 times the 
average weekly lead intake 
of Western populations. 
Occurred in Australia with 
Ayurvedic tablets 
prescribed from India. 
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Author Product used Adulterant/ Contaminant Adverse Effects Comments 
Tang, et al. (2011) 
75 





















NSAID-related acute renal 
failure, subclinical and 
clinical thyrotoxicosis, 
tremor, irritability, 
thyrotoxic periodic paralysis 
and right heart failure 
resulting in death. 
Multiple adulterants (up to 
6) were found in single 
products.  Occurred in Hong 
Kong with products 
purchased from the 
internet, China, over the 






Due to the perception that CAM remedies and herbal products are ‘natural’ and therefore 
harmless, they are consumed by both adults and children. Over a 36-month period in 
Australia, there were 39 reports of CAM associated adverse reactions in children (aged from 
birth to 16 years old) 26. In 56% of these cases (n =22), the adverse events were associated 
with the use of medicinal CAM. In one of the cases, the cause of the adverse reaction was 
linked steroid contamination of herbal products26.  
In this next section, case studies of adverse effects from adulterated products will be 
summarised (Table 1-3) to highlight that, while under-reported, adulterated products are a 
clinically relevant problem for consumers, health professionals and government agencies.  
Weight loss supplements 
There are many case studies and reports of adverse reactions resulting from the consumption 
of adulterated and contaminated herbal medicines, including a systematic review by Ernst 2. 
A major area of CAM use is for weight loss, and case studies and reviews have identified 
numerous incidents of adverse reactions to adulteration (Table 1-3). A retrospective review 
in Hong Kong looked at psychosis associated with herbal slimming products and identified 16 
patients from 2004 to 2009 65. The products were found to be adulterated with fenfluramine, 
sibutramine and its analogues N-desmethyl-sibutramine and N-bisdesmethyl-sibutramine. 
More than one adulterant was detected in 14 of the products. While psychosis is not a 
common adverse reaction to sibutramine 27, the authors of this case review suggested that 
the patients may have inadvertently overdosed themselves, resulting in the adverse reaction, 
by using the products liberally under the belief that the products were purely herbal and 
therefore could not cause harm 65. Another case study involving adulteration with 
sibutramine saw a healthy 20-year old woman develop severe headache, vertigo and 
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numbness after taking a Chinese herbal medicine purchased over the internet to support 
weight reduction 24. Quantification showed that one capsule contained 27.4 mg of 
sibutramine; approximately double the highest single dose approved for use in Germany 24. 
Tang, et al. 75 looked at herbal slimming medicines in Hong Kong, analysing 81 weight-loss and 
slimming products after 66 cases of poisoning from 2004 to 2009. In the cases presented by 
Tang, et al. 75, two involved pulmonary hypertension from fenfluramine adulteration, one of 
which was fatal (heart failure). Fenfluramine was a widely used appetite suppressant in the 
1980s and 1990s until its withdrawal from the market due to the fact that it can cause 
pulmonary hypertension and valvular heart disease 15,75. The products also contained a 
number of other adulterants, including sibutramine, mazindol, phenolphethalein, 
anthraquinones, bisacodyl, hydrochlorothiazide and spironolactone, drug analogues and 
animal thyroid tissue. Multiple adulterants (up to 6) were found in single remedies. The 
adverse reactions were consistent with the adulterant(s) found in the product and included 
cardiovascular effects such as palpitation, tachycardia, myocardial infarction and 
hypertension.  
Fenfluramine has been found in a number of different Chinese herbal medicines, particularly 
unnamed yellow pills for weight loss in studies presented by Corns and Metcalfe 15. The first 
patient had developed hypertension, weight loss and abdominal pain after taking four yellow 
pills per day over four months for ‘weight loss and appetite suppression’. This patient was 
also taking a number of other herbal medicines, in total 45 pills a day; another instance of a 
patient taking multiple herbal products, which can itself lead to drug interactions and 
complicate any diagnosis 38,75. In the second case, the patient became ill with rapid heart 
palpitation, nausea and visual hallucinations. The patient had been given no dosage 
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information by the herbalist and took about eight capsules, believing them ‘herbal’ and 
‘harmless’. In the third case study, the pregnant and breastfeeding patient had been assured 
by the same herbalist that the tablets were pure herbs and could not cause harm. After media 
reporting of the case studies, 14 further people came forward having taken either the same 
or similar herbal slimming products. In total 19 herbal slimming products, all imported from 
China, were collected and it was confirmed that the unnamed yellow pills contained 20 mg 
fenfluramine hydrochloride 15.  
Diabetes-related supplements 
While Lim, et al. 26 found that the biggest risk of CAM remedies was a rejection of conventional 
medicines in favour of CAM, Wood, et al. 76 present a different view. A 48-year old man with 
Type 2 diabetes had poor weight and glycaemic control, despite twice daily insulin and oral 
metformin. Complications included ischaemic heart disease needing coronary bypass surgery. 
After a year of no follow-up in which time the patient travelled to India and stopped all 
diabetic medication, the patient returned to the UK with excellent glycaemic control. While 
in India, the patient had taken three different herbal balls, three times a day with meals. 
During this time there were no hypoglycaemic episodes and no side effects from the herbal 
balls. Analysis of the herbal balls revealed that one of them contained chlorpropamide. 
Chlorpropamide is no longer recommended for use in the management of diabetic patients, 
particularly those with a history of cardiac disease (like this patient), due to the risk of serious 
side effects 76. However, in this case, there was clearly a benefit to the patient. 
There was a cluster of hypoglycaemia in Hong Kong in male patients from 2007 to 2008 38. 
The outcomes for 68 patients ranged from full recovery to 3 fatalities, with one patient 
remaining in a vegetative state and another with permanent cognitive impairment. The 
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hypoglycaemia was suspected to have been drug-induced, and urine testing showed the 
presence of sildenafil and glibenclamide (or metabolites). Many of the patients denied the 
use of the drugs, but 56% did admit to using non-prescription erectile dysfunction products, 
and 14 of these patients surrendered 25 unused products for analysis. In all, there were seven 
distinct CAM products. Both sildenafil and glibenclamide were detected in the products at 
various levels; both sub-therapeutic and at several times the maximum recommended daily 
dose. In some cases, one capsule/tablet contained enough glibenclamide to cause 
hypoglycaemia. It was strongly noted in this study that the reluctance of the patients to reveal 
their use of the CAM products hindered determination of the scale of the cluster. Patients 
with milder symptoms may not have sought treatment 38, meaning that the true extent of the 
incident remains unknown.  
Heavy metal contamination 
Contamination with pesticides or heavy metals 20 can also be the cause of adverse reactions 
to CAM remedies. Lead and mercury contamination of Ayurvedic tablets taken by a pregnant 
mother resulted in the chronic lead poisoning of herself and her infant in Australia with the 
products prescribed in India 74. At the time of publishing, the case study by Tait, et al. 74 
reported neonatal blood lead level were the highest recorded for a surviving infant, with lead 
concentrations of 11.8 µmol/L. The mother had been taking several tablets periodically for 
nice years, with the lead content being 4.5% to 8.9% in two tablets. Her blood lead 
concentrations were 5.2 µmol/L, the recommended public health levels are ≤ 0.48 μmol/L 74.  
Amster, et al. 28 presented a case of arsenic toxicity in a 54-year-old woman in California, USA. 
For two years, the patient had been suffering from worsening alopecia and memory loss to 
the point that she could no longer remember her home address. With no clear diagnosis, the 
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patient had taken to self-treatment with kelp supplements, fish oil, ginkgo biloba and grape 
seed extract. The symptoms were thought to be related to menopause, however, hormonal 
treatment had no effect. The patient increased her dose to at least four pills of kelp 
supplement per day, and her symptoms worsened to include diarrhoea, nausea, vomiting and 
daily pressure headaches. A urine test showed elevated arsenic levels, and analysis of the kelp 
supplement revealed an arsenic concentration of 8.5 mg/kg. The patient was advised to stop 
taking the supplement, and within three weeks, there was a near complete resolution of 
symptoms. The patient’s urine arsenic levels had returned to normal within two months. The 
intensity of the patient’s symptoms was most likely due to a long duration of exposure 28. 
The case by Amster, et al. 28 is another key example of a patient self-treating with herbal 
medicines and increasing dosages without any medical supervision. Not only does this case 
raise the issue of ‘natural’ does not equal harmless, but it also shows how such contamination 
or adulteration can complicate and dramatically lengthen the time of diagnosis and accessing 
the correct treatment for a patient, a point also apparent in Poon, et al. 38. The clinical 
relevance of adulteration and contamination needs to be further publicised, and more 
education is needed for the general public to build awareness of the potential health risks 
surrounding herbal medicines.  
Conclusion 
The call for stricter regulation of herbal medicines and dietary supplements has been 
repeated throughout the literature 38,64,77. Effective pre- and post-market screening and 
surveillance of CAM products is one method which would allow for the detection of 
adulterated or contaminated products and the withdrawal of products from the market 5, 
hopefully before adverse outcomes for consumers. The ideal outcome is the establishment 
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of more rigorous standardised methods for the analysis of CAMs that can be implemented in 
any regulatory jurisdiction. So what is next? Adulteration of herbal products is not a new 
problem, yet it is one for which there appears to be little political will to combat via regulation. 
While the issue is partly about misleading consumers, adulteration can have serious clinical 
implications, including mortality. The question is no longer ‘if’ tougher regulation and pre- 
and post-market screening are needed; but rather ‘how’ we can achieve these needs. 
Methodologies to screen herbal medicines have been developed, with numerous published 
studies outlining high-throughput and rapid methods. Screening approaches for regulation 
could be adapted from the existing literature, although refinement would be needed. Beyond 
science and technology approaches, further research is also needed into regulatory 
effectiveness in preventing these problems.  At the end of the day, so-called ‘low risk’ 
products used every day for self-treatment by consumers, should actually be low risk.  
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2. Toxicological screening and DNA sequencing detects contamination 
and adulteration in regulated herbal medicines and supplements 
for diet, weight loss and cardiovascular health  
 
Crighton, E., Coghlan, M. L., Farrington, R., Hoban, C. L., Power, M. W. P., Nash, C., Mullaney, 
I., Byard, R. W., Trengove, R., Musgrave, I. F., Bunce, M. & Maker, G. Toxicological screening 
and DNA sequencing detects contamination and adulteration in regulated herbal medicines 
and supplements for diet, weight loss and cardiovascular health. Journal of Pharmaceutical 
and Biomedical Analysis 176, 112834, doi:10.1016/j.jpba.2019.112834 (2019). 
 
Link:  
There is a lack of accessible data on the quality of CAM products on the Australian market. 
This chapter forms a part of research into the problems of adulteration, contamination and 
mislabeling of products on purchased in Australia by the authors. Novel to this research is the 
use of a combination of DNA metabarcoding and mass spectrometry techniques to investigate 






Use of herbal medicines and supplements by consumers to prevent or treat disease, 
particularly chronic conditions continues to grow, leading to increased awareness of the 
minimal regulation standards in many countries. Fraudulent, adulterated and contaminated 
herbal and traditional medicines and dietary supplements are a risk to consumer health, with 
adverse effects and events including overdose, drug-herb interactions and hospitalisation. 
The scope of the risk has been difficult to determine, prompting calls for new approaches, 
such as the combination of DNA metabarcoding and mass spectrometry used in this study. 
Here we show that nearly 50% of products tested had contamination issues, in terms of DNA, 
chemical composition or both. Two samples were clear cases of pharmaceutical adulteration, 
including a combination of paracetamol and chlorpheniramine in one product and trace 
amounts of buclizine, a drug no longer in use in Australia, in another. Other issues include the 
undeclared presence of stimulants such as caffeine, synephrine or ephedrine. DNA data 
highlighted potential allergy concerns (nuts, wheat), presence of potential toxins (Neem oil) 
and animal ingredients (reindeer, frog, shrew), and possible substitution of bird cartilage in 
place of shark. Only 21% of the tested products were able to have at least one ingredient 
corroborated by DNA sequencing. This study demonstrates that, despite current monitoring 
approaches, contaminated and adulterated products are still reaching the consumer. We 
suggest that a better solution is stronger pre-market evaluation, using techniques such as that 





Pharmacovigilance, mass spectrometry, toxicology, DNA metabarcoding, next generation 
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Background: 
Complementary and alternative medicine (CAM) therapies include acupuncture, 
aromatherapy, chiropractic, homoeopathy, traditional medicines, herbal and botanical 
medicines and dietary or food supplements. In the United States (USA) and Australia, at least 
50% of the population uses some form of CAM, often without the knowledge or support of 
their primary practitioner 78. In spite of increased usage and awareness of CAM, there persists 
the idea among consumers that, as many of these CAM treatments and remedies are 
promoted as ‘natural’, they are also harmless and essentially considering ‘natural’ to be 
equivalent to ‘safe’ 16. These ideals have proven to be false, with reports of drug-herb 
interactions, adverse effects and hospitalisation 79. An Australian survey on the use of 
complementary and alternative medicines (CAM) in people with Type 2 diabetes and/or 
cardiovascular disease (CVD) found that the average annual expenditure on CAM products 
was A$360 per person 80. Bailey, et al. 81 stated that consumers are moving towards a more 
integrated approach to medicine, with the implied aim to prevent or treat disease. In many 
cases, treatment for such diseases focuses on management rather than ‘cure’, motivating 
patients to look for alternative therapies. Cohen and Ernst 82 effectively summarised the 
concerns for CVD patients using herbal supplements, finding that there is a broad range of 
potential risks posed to such patients with under-reporting of adverse effects and drug-herb 
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interactions. Since there is an assumption of safety, patients will often not indicate 
supplement use and need to be directly asked about their herbal supplement consumption82. 
In addition to safety concerns, there are well-documented quality control problems with CAM 
29. Australia currently has some of the most stringent regulations of CAM products 83. Yet, 
post-market compliance reviews conducted by the Australian Department of Health have 
shown that during the 2016-17 period, 79% of products reviewed breached the current 
regulations, consistent with previous data 84. Notably, the 2016-17 performance report states 
that the ‘increase in the number of compliance reviews in recent years has not driven any 
improvement in compliance rates’ 84. These consistent levels of regulatory non-compliance 
prompted a review 85, which made several recommendations that have been accepted by the 
Australian Government, including changes to indications for use and advertisement of CAM 
products, and increased post-market surveillance 86 of the estimated 11,000 CAM products 
currently listed on the Australian Register of Therapeutic Goods (ARTG).  
Regardless of these proposed changes, there remains an established level of regulatory non-
compliance for CAM products, with a reliance on manufacturers making truthful and accurate 
declarations regarding the composition and manufacturing conditions of their products. 
Assumptions of regulatory compliance contradict data from post-market testing, as well as 
the current literature examining the wider CAM industry 20,23,29. In Australia, natural health 
products were the largest selling over-the-counter products in 2015-16 (A$1.4 billion) as well 
as the fastest growing 87. With the CAM industry expected to be worth an estimated US$180 
billion by 2020 88, there is a strong economic motivation to ‘improve’ products, often with the 
use of undisclosed ingredients 22. Previous studies into discrepancies between product 
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content and listed ingredients have reported undeclared plant materials, ingredient 
substitution, pharmaceutical adulteration and contamination with heavy metals 20,23,29.  
It was the aim of this study to investigate these quality control issues in CAM samples 
indicated for cardiovascular health, general wellness/wellbeing, and diet issues, including 
weight loss, gastrointestinal health and metabolism support, using a combination of DNA 
metabarcoding and advanced mass spectrometry techniques (LC-MS). One hundred thirty-
five products purchased in Australian capital cities and online were analysed using this multi-
faceted biomolecular survey.  
Methods: 
Samples:  
135 CAM products were purchased from pharmacies, health food stores, traditional herbal 
retailers and online in Australian capital cities from 2014 to 2017. The samples existed in a 
variety of formulations including tablets, capsules, gel capsules, tea, chewable tablets and 
gummies (or jubes), honey, liquids and powders, and were from various origins such as 
traditional Chinese medicine (TCM), Ayurvedic and Western herbal medicines and 
supplements. The products were aliquoted for analysis using aseptic techniques and allocated 
random identification numbers. Duplicate samples (for Samples 78, 186 and 253) were two 
different batches of the same product, noted by “1” and “2”. Samples 296 and 307 each 
consisted of two separate tablets or pills, which were analysed separately. 
DNA extraction and quantification: 
The DNA extraction procedure followed methods previously described 20,89. Quantification of 
the extracted DNA was carried out through polymerase chain reaction (PCR) amplification of 
a plastid gene region using the universal primers trnLgh and a mammalian mitochondrial DNA 
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gene region targeting a fragment of the 16S rRNA  (see Coghlan, et al. 20 for primer details). 
All PCRs were carried out using an ABI StepONE Plus qPCR platform (Applied Biosystems, USA) 
in a 25 μL volume including: 2 mM MgCl2 (Applied Biosystems, USA), 1 × Taq polymerase 
buffer (Applied Biosystems, USA), 0.4 μM dNTPs (Astral Scientific, Australia), 0.1 mg bovine 
serum albumin (Fisher Biotec, Australia), 0.4 μM of each primer, 0.2 μL of AmpliTaq Gold DNA 
polymerase (Applied Biosystems, USA) and SYBR-Green dye. Each sample was amplified using 
the undiluted extract and two dilution points (1:10 and 1:100) to gauge template copy 
number and identify if PCR inhibitors were present. The qPCR conditions were: 50 cycles of 
95°C for 30 s, annealing at primer specific temperature  for 30 s, and extension at 72°C for 
30 s. 
Amplicon generation: 
Previously described in 20,89, fusion primers with unique 6-8 bp multiplex identifier (MID) tags 
were designed for the same plant and mammal primer sets as used for the qPCR above, but 
with the inclusion of a second chloroplast gene region, rbcL (see Coghlan, et al. 20 for primer 
details). Fusion tag PCR was carried out using the same cycling conditions, with duplicate 
reactions for each DNA extract. Amplicons were blended into a library pool in equimolar 
amounts, as determined by amplicon concentrations on a Labchip GX Touch HT instrument 
(PerkinElmer, MA, USA). The pooled library was size selected on a Pippin Prep (Sage Sciences) 
using a 2% agarose gel with ethidium bromide cassette to exclude any primer dimer and 
cleaned over a QIAquick PCR Purification kit column (Qiagen, USA) following manufacturer’s 
instructions. The final purified library was again quantified on the Labchip GX Touch HT to 
determine the optimal amount of library required for sequencing. Amplicon sequencing was 
carried out on an Illumina MiSeq (Illumina, USA) according to manufacturer’s protocols using 




The data analysis has been previously described in 20,89. The sequencing output files were 
retrieved, filtered and processed using Geneious (v8.1). Samples were deconvoluted 
according to their unique MID tags, with reads that did not match exactly to the primers and 
MID tag sequences at both amplicon ends being filtered out. Reads were dereplicated in 
Geneious and exported for chimera removal in USEARCH using the UCHIME de novo method, 
along with singletons, and uploaded onto a high performance computer (Magnus - Pawsey 
Supercomputing Facility, Perth, Australia) where a BLASTn search was conducted against the 
National Centre for Biotechnology Information (NCBI) GenBank NR database. The resultant 
BLAST files were imported into the program MEtaGenome ANalyzer (MEGAN v4.7) for 
taxonomic analysis. The lowest common ancestor parameters for sequence assignments 
were: min score of 65, top percent of 5, and min support of 1. Taxonomic assignments for 
each sample were evaluated using available databases, and conservative estimates of 
families, genera and species were made.  
Toxicological analysis: 
Toxicological analysis for contaminants and adulterants such as conventional pharmaceuticals 
and pesticides was carried out using methods previously detailed in Hoban, et al. 89. Samples 
were crushed, and 50 mg was extracted by two methods, ethanol and basic ammonia 
extractions. Ethanol (EtOH) extraction: 1 mL of absolute EtOH (analytical reagent grade; 
Univar, Sydney AU) with 25 µL of internal standard mixture (see Supplementary Table 9-1) 
was added to the crushed sample, sonicated and centrifuged. The supernatant was 
evaporated to dryness and reconstituted with 100 µL of absolute EtOH before analysis. Basic 
extraction: 1 mL of glass distilled water and 250 µL of 30% ammonia (analytical reagent grade; 
Chem-Supply, Adelaide AU) were added to the crushed sample and vortexed. 5 mL of high 
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purity butyl chloride (BuCl; Honeywell, Adelaide AU) was added, and samples further 
extracted for 15 min using a mechanical roller and then centrifuged. The BuCl layer was 
evaporated to dryness and reconstituted with 100 µL of absolute EtOH before analysis.  
Sample extracts were analysed on an Agilent 1200 HPLC-6510 quadrupole time of flight-mass 
spectrometer (LC-QTOF-MS) (Agilent Technologies, USA) in positive ESI, auto-MS/MS mode 
with an Acquity BEH C18 column (1.7 µm, 3.0 x 50 mm; Waters, USA) and a Phenomenex C18 
4.0 x 3.0 mm guard cartridge (Phenomenex, USA). Mobile phases A and B were acetonitrile 
and aqueous 0.1% formic acid, respectively, with the following gradient: 0-0.5 min: 90% B, 
0.5-8 min: 90-50% B, 8-10 min: 50-5% B, 10-12 min: 5-0% B, 4-min post-gradient equilibration 
at 90% B. Total run time was 12 min with a 0.35 mL/min flow rate, increased to 0.4 mL/min 
for the last 2 min. An injector program was utilised which allowed mixing of 2 µL of the 
ethanolic sample extract with formic acid buffer prior to injection. The source temperature 
was set to 350°C, capillary voltage was 3000 V, and gas flow was 10 L/min. Skimmer and 
fragmentor voltages were 65 and 125 V, respectively. The analysis was repeated on an Agilent 
1100 HPLC with diode array detector (LC-UV), using an Agilent Eclipse Plus C18 column (1.8 
µm, 4.6 x 50 mm) with C18 guard cartridge (4.0 x 3.0 mm; Phenomenex, USA). Sample extracts 
underwent further analysis on an Agilent 7890 gas chromatograph with nitrogen-
phosphorous and mass spectrometer detectors (GC-NPD/MSD). 
Results were processed using MassHunter Qualitative Analysis (vB.07.00) for LC-QTOF-MS 
data, ChemStation for LC (vB.04.01) for LC-UV data and MSD ChemStation (vE.02.00.493) 
software for GC-NPD/MSD data. Peaks were matched against Forensic Science SA’s in-house 
retention time, accurate mass and MS/MS spectral library of approximately 350 compounds, 
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and a commercial database containing 3,490 MS/MS spectra (Forensic and Toxicology 
Personal Compounds Database and Library, Agilent Technologies).  
Caffeine and paracetamol were quantified using the ethanol extraction described above with 
analysis by LC-UV. Buclizine and chlorpheniramine were quantified using the basic extraction 
with LC-QTOF-MS analysis, as described above. For quantitation of synephrine, ephedrine and 
the ephedrine analogues, samples were extracted with 2 mL of sodium acetate buffer (pH 
5.7), sonicated and vortexed. The supernatant was passed through a solid phase extraction 
(SPE) cartridge (200 mg/3 mL XTRACT; UCT, USA) and eluted with CH2Cl2/propan-2-ol. The 
eluent was evaporated to dryness and reconstituted with methanol. These samples were 
analysed using an Agilent 1200 HPLC coupled to a Sciex 4000 QTRAP-MS system (Sciex, USA) 
in positive ESI multiple reaction monitoring (MRM) mode. Mobile phases A and B were 
methanol and aqueous 0.1% formic acid. Total run time was 9 min with a 0.80 mL/min flow 
rate. Source temperature was set to 650°C, ion spray voltage was 4000 V, ion spray gas was 
70 psi, and curtain gas was 30 psi. Calibration curves from reference standards (run in parallel 
with samples) were used to determine adulterant/contaminant concentrations. 
Results: 
Figure 2-1 shows the comparison between the samples listed/not listed on the ARTG, while 
detailed individual sample results can be found in Supplementary Table 9-2. Overall, 86 
samples (63%) were listed with the TGA and could be found on the ARTG. Of the total sample 





Of the 137 samples, 40% (n = 55) were found to contain no amplifiable DNA. Of those samples 
which did contain DNA (n = 82), 51% (n = 42) had additional plant DNA, 30% (n = 25) contained 
commonly used ‘filler’ ingredients such as soybean, rice, oat, wheat or grasses, 4% (n = 3) had 
additional animal DNA (DNA from non-domestic animals not listed or related to ingredients) 
and 21% (n = 17) had animal contamination (DNA from domestic species such as dog, pig, rat, 
mouse or cow).  
Figure 2-1 B and C show the difference in DNA results between ARTG listed and non-listed 
samples. In the ARTG listed products for which DNA data could be generated, 44% (n = 21) 
had stated ingredients confirmed, 65% contained additional plant DNA, 27% contained filler 
ingredients, 2% contained additional animal DNA, and 31% had animal contamination. For the 
products not listed on the ARTG (n = 34), only 24% had stated ingredients confirmed, 32% had 
additional plant DNA, 35% contained filler ingredients, 6% contained additional animal DNA 
and 6% contained animal contaminants.  
Overall, only 22% (n = 30) of the samples could be considered to have had ingredients 
confirmed by this analysis, with taxonomic assignment corroborating the presence of an 
ingredient listed on the sample packaging. However, some of these samples also contained 




Figure 2-1: A) Compassion between the categories of adulteration, contamination and 
undeclared ingredients of the samples listed/ not listed on the ARTG. B and C) The DNA results 
from the samples listed (B, green) and not listed (C, black) on the ARTG which contained DNA. 
Percentage of samples in each category is shown.   *DNA from plants or animals listed as main 




Most of the samples were negative for pharmaceuticals (74%, n = 101). Of those samples 
which did contain pharmaceuticals, 20% (n = 27) were declared on the label or explained by 
the ingredient list, such as caffeine from green tea or synephrine from bitter orange. 19% (n 
= 26) of samples contained caffeine, 14 of which were listed and 12 not listed on the ARTG. 
5% (n = 7) of the samples contained additional unexplained pharmaceuticals, including 
caffeine, synephrine, ephedrine and related alkaloids, paracetamol, chlorpheniramine and 
trace amounts of mycophenolic acid and buclizine (Table 2-1). Of these seven samples, six 
were listed on the ARTG. 







Pharmaceuticals Amount  
(mg/ pill) 
Dose per day Maximum total daily 
intake (mg) 
44 Y Synephrine 0.69 Take 3 capsules, 
three times a day 
6.2 
86 Y Buclizine 0.0002 Take 1-2 tablets daily 
or ‘for a quick energy 
boost’ take 2-4 
tablets 
0.0008 
93 Y Ephedrine 0.0001 Not Given N/A 
162 Y Mycophenolic acid Trace 
levels 
Take 1 tablet daily N/A 
296 B N Paracetamol 0.16 Take 1, twice a day 0.32 
Chlorpheniramine 0.0017 0.0034 
322 Y Ephedrine  0.0016 Take 1 capsule once 
or twice a day 
0.0032 









The data generated in this study continues to highlight a number of concerns with herbal CAM 
products 20,89. The large number of products containing undeclared plant ingredients indicates 
either widespread ingredient substitution or that current methods used to identify plant 
ingredients are inadequate. Many products were contaminated with animal DNA that cannot 
be explained based on the ingredient list and may speak to poor manufacturing processes. 
5% of the samples contained undeclared pharmaceuticals, at least two of which are clear 
cases of adulteration (samples 296 B and 322).  
 Genetic analysis: 
As found in our previous study 20 and elsewhere 23, the ingredient list for a product does not 
always reflect what is actually contained within that product. Of the 137 samples tested in 
this study, only 21% (n = 29) had at least one of the listed ingredients corroborated by DNA 
barcoding. Furthermore, DNA from plants not listed or related to the product ingredients was 
found in 31% of the samples, making it impossible for consumers and their medical 
professionals to determine exactly what an individual has ingested. This lack of regulatory 
compliance demonstrates serious shortfalls in quality control and/or manufacturing 
processes. DNA from the cashew nut (Anacardium) and the walnut (Juglandaceae) families 
were detected in samples 68 and 319, and 79, respectively, presenting possible nut allergy 
concerns. DNA from black walnut  (Juglans nigra)  was also detected 23 in single-herb products 
containing ginkgo. Further to this, 18% of samples contained filler ingredients, such as rice 
(Oryza) or soybean (Glycine). The presence of undeclared fillers is of particular concern to 
people with allergies (e.g. celiac disease). 
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Unknown ingredients and inaccurate labels increase the potential for adverse and allergic 
reactions because consumers cannot make informed choices 90. Not only this but in cases 
where an adverse reaction does occur, it will be very difficult to determine the causal agent 
if the ingredient list does not accurately reflect the contents. To highlight this point, sample 
80, indicated for assisting ‘healthy people to maintain cholesterol and triglycerides within the 
normal range’, contained DNA from the Neem tree (Azadirachta indica). Not declared on the 
label as an ingredient, the Neem tree has been widely used in Ayurvedic medicine 91 and has 
many potential bioactive properties. However, Neem oil has also been the cause of poisonings 
(mostly in children), causing vomiting, metabolic acidosis, and toxic encephalopathy 92. 
Products sold in Australia containing Neem oil for topical application need to be labelled with 
the warnings ‘not to be taken’ and ‘keep out of reach of children’.  
Not only was additional plant DNA detected, but in a small number of samples, additional 
animal DNA or contamination was detected. Contamination from species such as rat, dog, 
goat, pig and other domesticated animals is potentially from manufacturing deficiencies or 
transportation and could be seen as inadvertent 20. The detection of DNA from non-
domesticated animals is harder to explain. In sample 69, a supplement powder for general 
wellbeing, reindeer DNA (Rangifer tarandus) was detected, while in sample 245, a tea for 
‘slimming’ and ‘detox’, DNA was found from frog (subfamily Rhacophorinae) and the Asian 
Highland Shrew (Suncus montanus). Neither of these products declared animal ingredients, 
and it is possible that this was also inadvertent contamination. However, frog has previously 
been found in herbal products 20 and is a potential deliberate addition for zootherapy 93.  
Sample 70 raises questions of ingredient substitution or fraud 93. Listed only to contain shark 
cartilage (no species information given) and indicated for general wellbeing, as an anti-
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inflammatory and for joint health, the product had animal contamination from rat, dog and 
pig, as well as shark DNA from tiger shark (Galeocerdo cuvier) and Carcharhinus sp., indicating 
that the product was at least partly accurate in its ingredient declaration. However, there is 
also the possibility of ingredient substitution for bird cartilage rather than shark, with DNA 
found from Anatidae sp. and the subfamily Phasianinae. Both bird taxa were not reflected on 
the ingredient list. 
DNA barcoding provides vital information about the composition of a sample, but it does have 
limitations, particularly when no DNA is detected in a sample, as was the case with 40% of the 
samples in this study. This can be due to various factors, including the nature of the product 
ingredients (e.g. herbal extract), the form of the product itself (e.g. oil capsule) or the 
manufacturing process, where DNA can be totally degraded and therefore unable to be 
detected 94. Alternatively, it is possible some formulations contain no biological material so 
would never yield a DNA profile. The use of PCR methods for commercial testing has also been 
recently discussed in Newmaster, et al. 90, arguing for a transparent system and supply chain 
with well-defined common incidental DNA limit (such as the DNA from common domestic 
species detected in this study). Nevertheless, DNA degradation and its loss are key drivers for 
our suggested multi-tiered approach to pharmacovigilance for CAM products 20,94.  
Toxicological analysis: 
Caffeine was the most commonly detected compound in this study, in 19% of samples (n= 
26). The presence of caffeine is chiefly explained by ingredients such as green tea (Camellia 
sinensis), coffee (Coffea canephora) and Yerba Mate (Ilex paraguariensis). Caffeine has a long 
history of use in weight loss and diet products 95,96, and is one of the most widely consumed 
drugs worldwide 95. Due to the widespread and generally safe consumption of moderate 
47 
 
doses of caffeine (up to 400 mg/day) 95, Australian regulations only require a product to 
declare that it contains caffeine 97. Of the 27 products which were found to contain caffeine, 
the content was declared on the labels of 14, of which 12 were listed on the ARTG, fulfilling 
the labelling requirements. For samples on which this declaration was made or when caffeine 
was expected due to the ingredients, caffeine was not quantified in this study. Sample 243 
contained a small amount of caffeine (0.55 mg/g) which could not be explained by the listed 
ingredients, indicting possible contamination. 
Occurring naturally, Ephedrine and its related alkaloids are produced by plants in the Ephedra 
genus, also known as Ma Huang 98, which has a long history of traditional use. Recently, it has 
become more likely to be abused due to its effectiveness in weight loss and performance 
enhancement, and its stimulant effects. Adverse effects from taking herbal medicines which 
contain ephedrine are well documented and include cardiovascular and cerebrovascular 
complications 99. This has led to stricter regulations for ephedrine in most countries, including 
a 2004 ban in the USA 35. Ephedrine taken in combination with other stimulant drugs, such as 
caffeine or synephrine, is another potential risk to consumers 96, although, in this study, no 
products contained this combination.  
Sample 322 was positive for DNA from Ephedra and many other plant families and genera 
including Anthemideae, Astereae, Solanoideae, Acalypheae, Linum, Triticeae and Medicago. 
The sample indicated to ‘balance and support normal male physiology and function, enhance 
stamina and endurance during intense physical activity and maintain the production of 
testosterone levels in the body’, also contained DNA from the family Tribuloideae, which 
includes the only stated ingredient for this product, Tribulus terrestris extract. In Australia, 
Ephedra is restricted to prescription only, unless the total ephedrine content is less than 10 
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mg/kg or 0.001% 97. With 3 mg/kg or 0.0003% of ephedrine content, Sample 322 did not 
exceed the regulatory limits for ephedrine, but in other countries, the detection of Ephedra 
DNA alone would make this product illegal for sale. While the concentration of ephedrine was 
at trace levels, the larger concern with Sample 322 is that it is listed on the ARTG, indicating 
that it claims to comply with safety, quality and manufacturing requirements, despite clear 
evidence of non-compliance with labelling and quality requirements by the contamination of 
other plant species and no declaration of ephedrine content.  
Synephrine is another naturally occurring compound that was detected in this study, in 5% (n 
= 7) of samples. Structurally similar to ephedrine, synephrine occurs in many citrus species 
such as bitter orange (Citrus aurantium), and, like caffeine, has become popular in weight loss 
and diet assistance products. In the case of sample 44, none of the plants listed or found in 
the DNA screen (see Supplementary Table 9-2) are from genera known to contain synephrine 
and the levels that would be consumed in recommended doses of Sample 44 (6.2 mg) would 
be a threshold dose for pharmacological activity only. While the presence of the compound 
without the associated botanicals indicates was likely to have been added exogenously. 
Defining this addition as either contamination or adulteration with near-active concentrations 
is however difficult. 
Sample 296B contained paracetamol and chlorpheniramine (Table 2-1), suggesting deliberate 
adulteration of this product. Paracetamol is a common over-the-counter analgesic, however, 
dosage information must be followed, as overdose will result in hepatotoxicity. In cold and 
flu medication, paracetamol is often combined with an antihistamine such as 
chlorpheniramine. While chlorpheniramine is an over-the-counter medicine in Australia, the 
packet must carry a sedation warning, as impairment occurs even at low doses 100. As a first-
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generation antihistamine, the most common side effects are drowsiness, sedation, fatigue, 
coordination disturbances and impaired memory 101. Stated to be ‘suitable for people with 
high cholesterol levels, skin problems, simple obesity and for improvement of general health’, 
there appears to be no obvious reason for Sample 296B to contain this combination. 
Consumed in recommended doses, the intake of paracetamol and chlorpheniramine (0.32 
and 0.0034 mg, respectively) would be at or below the threshold for pharmacological activity, 
yet the presence of these synthetic drugs, even at sub-therapeutic amounts, again raises 
concerns about quality and manufacturing conditions.  
Trace amounts of buclizine and mycophenolic acid were detected in Samples 86 and 162, 
respectively, and were most likely contaminants from manufacturing. Both products were 
listed on the ARTG, and the presence of these drugs implies failings in manufacturing 
standards. Buclizine is a first-generation antihistamine that has been superseded by more 
successful drugs of its class. To the best of the authors’ knowledge, buclizine is not currently 
used in Australia, Europe or the USA, and is only available in the UK in combination with 
paracetamol and codeine (brand name Migraleve Pink) for treatment of migraine. The 
detection of trace amounts (0.2 µg/g) of this drug in Sample 86, a product purportedly 
manufactured in Australia and marketed for ‘increased energy, stress resistance, improved 
immunity, sexual function and healthy heart’ is of some concern. Mycophenolic acid, 
detected in trace amounts (below LOQ and not quantified) in Sample 162, is a prescription-
only immunosuppressant medicine. Once again, this drug should not have been found in any 
concentration in this product.  
The use of routine screening methods did limit the findings of this study. Samples were only 
analysed using positive ionisation and only therapeutically relevant LOQ values are achieved. 
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Despite these limited restrictions from the use of routine methods in this study, if safety and 
quality control measures of CAM products were sufficient, this study would report zero cases 
of undeclared pharmaceuticals in the ARTG listed products. Instead, clear cases of 
adulteration and the presence of pharmaceuticals of indeterminate (and often inexplicable) 
origin were demonstrated in both listed and non-listed products. 
Conclusion: 
Of the samples analysed in this study, 63% were listed on the ARTG (n = 86), meaning that 
these products have been assessed for safety and quality under current regulation, and are 
only allowed to contain approved ingredients 97. Those samples which were not listed with 
the TGA were purchased online, exempt from regulation (e.g. some homoeopathic products) 
or should not have been able to be purchased on the Australian market. The fact that the 
authors could purchase these products suggests a failure in regulatory control, demonstrating 
a clear need to strengthen the regulation of these products to improve consumer safety. 
While a worthy effort, increasing post-market testing will not keep non-compliant and 
potentially dangerous products from being sold in the first place. This study has shown that 
contaminated and adulterated products are not minor, niche-market remedies, but are sold 
in some of the biggest health food stores and pharmacies in Australia. Pre-market evaluation 
using the methods described here and in our previous studies 20,89 would provide an audit 
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3. Exploring the application of the DSA-TOF, a direct, high resolution 
time-of-flight mass spectrometry technique for the screening of 
potential adulterated and contaminated herbal medicines 
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Link: 
Following on from chapter 2, where contamination and adulterated products were found to 
be present in products on the Australian market, this study and Chapter 4 present the 
development and application of a rapid mass spectrometry screening method for herbal 
medicines to complement the methods detailed in Chapter 2 by expanding to an untargeted 





Global consumption of complementary and alternative medicines, including herbal 
medicines, has increased substantially, and recent reports of adulteration demonstrate the 
need for high throughput and extensive pharmacovigilance to ensure product safety and 
quality. Three different standard reference materials and five previously analysed herbal 
medicines have been used as a proof of concept for the application of 
adulteration/contamination screening using a DSA ion source with TOF MS on the Perkin 
Elmer AxION 2 TOF. This technique offers the advantages of minimum sample preparation, 
rapid analysis and mass accuracies of 5 ppm. The DSA TOF analysis correlates well with the 
previous analysis on the initial sample set (which found undeclared herbal ingredients), with 
the added advantage of detecting previously untargeted compounds, including species-
specific flavonoids and alkaloids. The rapid analysis using the DSA-TOF facilitates screening 
for hundreds of compounds in minutes with minimal sample preparation, generating a 
comprehensive profile for each sample. 
 
Keywords   
Herbal medicines, pharmacovigilance, adulteration, contamination, direct mass spectrometry 
 
 Introduction 
With the increasing use of complementary and alternative medicines (CAMs), the quality and 
safety of such products have been called into question. The 2017 global market for herbal 
medicines alone is currently estimated to be US$107 billion 29, and expected to reach US$115 
billion by 2020 17. The reasons behind this increased use are numerous, but the popular belief 
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that CAM products are ‘natural’ and therefore less harmful, with fewer side effects than 
conventional pharmaceuticals, has been suggested as a key reason for the observed growth 
17,102,103. There is now considerable data to challenge this assumption of safety, and CAM are 
estimated to cause 23,000 emergency department visits per year in the USA 13. Adulteration 
and contamination with pharmaceuticals, heavy metals and lower quality ingredients are not 
uncommon and should be a serious safety concern for consumers 20.  
Despite these concerns, regulation of CAM is often trust-based, so there is a pressing need 
for new tools to rapidly assess the safety of herbal CAM both pre- and post-market. Rather 
than using a multi-target analysis, the screening and detection of pharmaceutical adulterants 
in complex herbal matrices have mostly been focused on specific pharmaceuticals being 
added to herbal products with similar indications 20,44 (e.g., the adulteration of male sexual 
health products with sildenafil 39). This focused screening can miss contamination of products 
with pharmaceuticals of unrelated indications 20, drug isomers or novel compounds 60,61,104. 
The data 20,44,60,61,104 gathered to date clearly demonstrates the need for a rapid, multi-target 
or untargeted screening method. Until such a method is developed and a comprehensive 
screen of products on the market is undertaken, the scope of adulteration and contamination 
of herbal CAM products will remain unquantified.  
In this study we explore the use of a rapid, high-throughput screen for pharmaceutical 
adulterants using the AxION 2 Direct Sample Analysis-Time of Flight (DSA-TOF) mass 
spectrometer. This analysis needs minimal sample preparation and employs rapid, ambient 
ionization mass spectrometry via the DSA source coupled to a TOF for high resolution spectral 
data 105. This allows for tentative identification of possible adulterated or contaminated 
products through accurate mass and isotopic pattern matching without the requirement for 
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separation by chromatography. The resulting matches can then be rated in confidence, with 
subsequent confirmation and quantification of positive results by Liquid Chromatography-
Mass Spectrometry (LC-MS), such as employed in our previous work 20 and that by Bogusz, et 
al. 44. The benefits of this two-stage approach are that the more complex and time-consuming 
confirmatory analysis has a smaller sample load, the stratified scoring system allows for 
prioritising of samples, and the analysis is carried out over two platforms, giving greater 
confidence in the results. It was the aim of the study to determine if the DSA-TOF could be 
appropriate as a rapid screening tool for CAM products. We used NIST standard reference 
materials (SRMs) and five previously analysed CAM products as a proof of concept for testing 
the efficacy of DSA-TOF to detect adulteration and contamination in herbal CAMs and provide 
a rapid method for pharmacovigilance. 
Methods  
Materials 
Drug standards amoxicillin, aspirin, brucine, caffeine, chlorpheniramine, cyproheptadine, 
dexamethasone, diphenhydramine, ephedrine, ibuprofen, lignocaine, mianserin, 
paracetamol, prednisolone, ranitidine, salicylic acid, sildenafil, simvastatin, strychnine, 
tadalafil and warfarin were purchased from Sigma-Aldrich (Sydney, Australia) in the highest 
purity available. Codeine, diazepam, digoxin, sibutramine, streptomycin, tamoxifen, 
vardenafil, verapamil, yohimbine and the internal standard diazepam-D5 were purchased 
from Novachem (Melbourne, Australia) in the highest purity available. LC-MS grade methanol 
and water were purchased from Fisher Scientific (Hampton, USA).  
The NIST standard reference materials (SRM) used were Camellia sinensis (green tea) powder 
(SRM 3254), multivitamin tablets (SRM 3280) and Ginkgo-containing powder (SRM 3248). The 
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five CAM products (tablets, capsules and tea) were purchased in Australia in 2014 from 
pharmacies, health food stores and traditional herbal retailers. These products had been 
previously analysed 89 for heavy metal content, pharmaceutical adulteration and undeclared 
plant content via next generation DNA sequencing. The samples were indicated for various 
uses such as anxiety and depression, blood circulation, stress, ‘energy’, ‘brain function’, 
‘mental clarity’ and ‘mood’.  
Sample preparation 
The NIST SRM and CAM samples were ground to a fine homogenised powder using a Precellys 
lysing kit consisting of CKMix 50-R 2 mL tubes (Bertin Technologies, France). The sample 
extraction was based on our previous work 20. The powdered samples were transferred to 2 
mL lysis tubes and stored at -80°C until use. For methanol extraction, approximately 5 mg of 
each sample was weighed out in triplicate 2 mL lysis tubes. 1 mL of methanol was added, and 
samples were then shaken for 80 s at 6500 rpm in a Precellys tissue lyser (Bertin Technologies, 
France). After shaking, the extracts were centrifuged for 15 min at 13.2 x 104 x g. The 
supernatant was transferred to fresh 1.5 mL tubes and dried by evaporation using an 
Eppendorf Concentrator Plus rotary vacuum concentrator (Eppendorf South Pacific Pty. Ltd., 
Sydney, Australia). Dry extracts were stored at -80°C until use. For analysis, 1 mL of 10% 
methanol with 0.1% formic acid was added to the dried extracts and the samples shaken for 
10 min. 10 µL of reconstituted sample was then spotted for analysis. 
A standard mix of 30 drugs from various pharmaceutical classes (listed in 2.1 above) was used 
as a positive control and run in triplicate at the beginning of each day. The concentration of 




The DSA is a combined ambient ionisation source and sampling platform previously described 
in Botch-Jones, et al. 106 and Winter, et al. 105. DSA-TOF (PerkinElmer, Waltham, USA) 
conditions were as follows: positive acquisition mode, 350°C probe temperature, 60 psi 
nebuliser gas (N2) pressure, 4 L/min auxiliary gas flow and drying gas at 3 L/min and 25°C. The 
corona current was 4 µA, scan rate was 10 spectra/s, capillary entrance was set to 800 V, 
endplate heater was 200 V, and the capillary exit was 100 V. The total method run time was 
0.55 min., with a sample spot time of 30 s. The Agilent APCI-L low concentration tuning mix 
(Agilent Technologies, Santa Clara, USA) was used to calibrate the DSA-TOF before analysis 
each day and was also used as the internal ‘lock-mass’ calibrant during sample acquisition. 
Data analysis 
Spectral data were viewed and analysed using AxION SOLO software, and R. Raw spectra were 
scanned by AxION SOLO for matches to exact monoisotopic masses and isotope ratios of 
targeted compounds based on compound formula. Over 350 pharmaceuticals, analogues and 
phytochemicals were screened against an in-house library in this first step (Supplementary 
Table 9-3). After initial analysis in SOLO, the individual spectra of each sample were processed 
and analysed in R using locally developed code (see appendix for code). The enviPat R package 
107 (v2.2) was used to compile the isotopic patterns of the targeted compounds to compare 





 Standard compound mix 
Of the 30 pharmaceuticals in the standard mix, 21 were consistently detected (Figure 3-1): 
brucine, caffeine, chlorpheniramine, codeine, cyproheptadine, diazepam, diphenhydramine, 
ephedrine, lignocaine, mianserin, paracetamol, ranitidine, sibutramine, sildenafil, strychnine, 
tadalafil, tamoxifen, vardenafil, verapamil, warfarin, and yohimbine. Compounds not 
detected were: amoxicillin, aspirin, dexamethasone, digoxin, ibuprofen, prednisolone, 
salicylic acid; simvastatin and streptomycin; reasons for these non-detections are discussed 
below. 
NIST standard reference materials 
Table 3-1 shows the data from DSA-TOF analysis of the three NIST SRMs: Camellia sinensis 
(green tea) powder, multivitamin tablet and ginkgo powder. The certified composition is 
compared to that detected by the analysis. 
Camellia sinensis (green tea) powder 
The expected content of the SRM was caffeine, catechin, epicatechin, epicatechin gallate, 
epigallocatechin, epigallocatechin gallate, gallic acid, gallocatechin, gallocatechin gallate, L-
theanine and theobromine. Caffeine, catechin/epicatechin, and epigallocatechin/ 
gallocatechin were all detected with errors less than 5 ppm for the respective molecular ions 
[M+H]+. The diastereoisomers catechin/epicatechin and epigallocatechin/gallocatechin 
cannot be distinguished using this method, so are referred to collectively. Gallic acid and 
theanine were also putatively identified, but with higher errors of 10.52 and 9.71 ppm, 
respectively. Kaempferol and quercetin were also detected, but are not listed on the 
certificate of analysis for this NIST standard. These compounds, however, are known to occur 
in green tea, and several other plants 108. Theobromine was also detected, but with a high 
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ppm error (>10 ppm). The gallic acid esters, epicatechin gallate, epigallocatechin gallate and 
gallocatechin gallate were not detected.  
Multivitamin tablet 
The NIST multivitamin tablet was certified to contain the following vitamins and carotenoids: 
α-tocopherol, ascorbic acid, biotin, cis-β-carotene, cyanocobalamin, ergocalciferol, folic acid, 
lutein, nicotinamide, pantothenic acid, phylloquinone, pyridoxine hydrochloride, retinol, 
riboflavin, thiamine hydrochloride and trans-β-carotene. In the DSA analysis, pantothenic acid 
and pyridoxine were identified with 4.69 and 4.51 ppm error, respectively. Nicotinamide, 
thiamine and riboflavin were also identified, but had errors >10 ppm. None of the fat-soluble 
vitamins were detected, however these compounds were not expected to be extracted or 
detected using the methodologies employed here. 
Ginkgo powder 
The ginkgo powder was listed to contain bilobalide, ginkgolides A, B, C and J, isorhamnetin, 
kaempferol and quercetin. Isorhamnetin (5.05 ppm error), kaempferol (1.98 ppm error) and 
quercetin (5.17 ppm error) were all detected by the DSA-TOF analysis. However, none of the 
terpene lactones (ginkgolides and bilobalide) were identified. There was also an alkaloid-like 
compound that was detected, but not definitively identified. 
CAM products 
 Table 3-2 shows the data from the DSA-TOF analysis compared with a previous investigation 
using next generation DNA sequencing (NGS) and LC-MS 89. The previous analysis of the 
samples had shown no contamination or adulteration with heavy metals or pharmaceuticals. 
Due to the processing of the products, which are mostly extracts, DNA material was not 
expected to be recovered in 3 of the 5 samples. These Ginkgo biloba products, samples 92 
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and 157, showed the same contents as the ginkgo SRM with isorhamnetin, kaempferol and 
quercetin all detected. The Skullcap tea, sample 175, also contained isorhamnetin, 
kaempferol and the flavonoid wogonin. All the compounds in samples 92, 157 and 175 had 
errors ≤ 5 ppm. 
The ingredients listed for sample 73 were vitamins ascorbic acid, biotin, calcium 
pantothenate, cyanocobalamin, nicotinamide, pyridoxine hydrochloride, riboflavin sodium 
phosphate, thiamine hydrochloride, Eleutherococcus senticosus (Siberian Ginseng) and 
Paullinia cupana (Guarana). Caffeine was detected in both analyses of sample 73; 
nicotinamide, pantothenic acid, pyridoxine and trigonelline were also detected. All the 
compounds detected in sample 73 had errors < 5 ppm.  
The multivitamin, sample 100, was listed to contain several B vitamins including calcium 
pantothenate, nicotinamide and pyridoxine hydrochloride, along with Rhodiola rosea, 
calcium hydrogen phosphate, choline bitartrate, chromium picolinate, inositol, potassium 
sulphate and zinc sulphate monohydrate. Similar to the SRM multivitamin, only nicotinamide, 




Figure 3-1: DSA spectra and ppm error for 18 of 21 detected pharmaceutical standards. From left to right: Ephedrine, paracetamol, caffeine, 
lignocaine, diphenhydramine, mianserin, chlorpheniramine, diazepam, codeine, rantidine, strychnine, yohimbine, tamoxifen, brucine, verapamil, 




Table 3-1: Data from DSA-TOF analysis of the three NIST SRMs. Ingredients detected by the 
DSA analysis are listed in bold. # Indicates compounds that were detected with error rates 
above 10 ppm.  
NIST # Certified composition 
(vitamin) 

















Caffeine (4.96 ppm) 
Catechin /Epicatechin (2.18 
ppm) 
Epigallocatechin/Gallocatech
in (1.63 ppm) 
Gallic acid (10.52 ppm) 
Kaempferol (2.32 ppm) 
Quercetin (1.10 ppm) 







Ascorbic acid (C) 
Biotin (B7) 
Folic acid (B9) 
Nicotinamide (B3) 




Thiamine hydrochloride (B1) 
Pantothenic acid (4.69 ppm) 









phylloquinone and retinol 
are also a part of the SRM 
composition. However, 
these compounds were 
either gel encapsulated fat-
soluble vitamins or outside 
of the mass range and were 
not expected to be extracted 










Isorhamnetin (5.05 ppm) 
Kaempferol (1.98 ppm) 
Quercetin (5.17 ppm) 
Catecholamine and alkaloid-
like compounds were 






Table 3-2: Comparison of analytes detected in five CAM samples using DSA-TOF analysis 
against that found using a combination of LC-MS and next generation DNA sequencing. 
Ingredients and previously detected compounds and DNA which agree with the DSA analysis 
are listed in bold. * Indicates that catecholamine and alkaloid-like compounds were detected 
but not definitively identified.  
CAM # Ingredients (vitamin) Previous analysis Comment on 
previous analysis 
DSA ID (error) 

















Homo sapien DNA 
Rutaceae sp. (citrus) 
DNA  
Caffeine expected 
based on ingredient 
list (Paullinia 
cupana) 









92 Ginkgo biloba Nothing detected DNA detections not 











CAM # Ingredients (vitamin) Previous analysis Comment on 
previous analysis 
DSA ID (error) 




pantothenate (B5)  




Folic acid (B9)  
Inositol 
Nicotinamide (B3)  





Thiamine nitrate (B1) 
Zinc sulphate 
monohydrate 
Nothing detected DNA detections not 






(9.54 ppm)  
Pyridoxine (9.02 ppm) 
 
157 Ginkgo biloba extract Nothing detected DNA detections not 





Quercetin (2.64 ppm) 
Isorhamnetin (1.05 
ppm)* 
175 Organic Skullcap tea DNA detected:  
Canis lupus familiaris  

















This paper aimed to assess the appropriateness of the DSA-TOF as a rapid, high-throughput 
screening method for herbal medicines/CAMs. A high-throughput approach has been 
advocated by the authors 19 to aid the implementation of a more thorough approach to pre- 
and post-market auditing and overall regulation of herbal CAMs. Until such a method is 
developed and a comprehensive screen of products on the market is undertaken, we will not 
have a clear picture of the scope of contamination and adulteration of herbal CAM products.   
The obvious benefits of the DSA-TOF method are rapid analysis and minimal sample 
preparation, as seen in this study where simple methanol extracts were each analysed in less 
than 1 min.  
Another benefit of this method is the collection of untargeted data; with the method only 
becoming ‘targeted’ when a specific library is applied during data analysis. In this study, the 
target database consisted of over 300 pharmaceuticals, vitamins, phytochemicals and 
analogues of these compounds. This broad coverage, coupled with the ability for 
retrospective analysis beyond the original target database, is a substantial benefit of the DSA-
TOF analysis. In some cases, the DSA-TOF was unable to detect certain standards: amoxicillin, 
aspirin, dexamethasone, digoxin, ibuprofen, prednisolone, salicylic acid, simvastatin and 
streptomycin (see Supplementary Table 9-4 for predicted detections). As the analysis was only 
carried out in positive ion mode, detection of aspirin, ibuprofen and salicylic acid was not 
expected, as these compounds are typically analysed in negative ion mode 41. As the DSA is a 
modified APCI source 105, the inability to detect amoxicillin, dexamethasone, prednisolone 
and streptomycin was possibly due to the low volatility or high polarity of these compounds. 
However, this method still has the potential to give a good indication of what a product does 
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or does not contain with 70% of the target pharmaceutical standards detected with less than 
a 1-min analysis. With the use of negative mode, the coverage of this method could be 
improved further. More crucially the common adulterants sibutramine, sildenafil and  
tadalafil can be detected. In the first 6 months of 2018, these three drugs have been 
responsible for 14 regulator health alerts in Australia after being detected in counterfeit 
products 109. 
The absence of chromatographic separation reduces the level of assurance and confidence in 
the identification of compounds. Analysis of the multivitamin SRM detected only 25% of the 
contents within an acceptable ppm range (Figure 3-2), highlighting the challenges posed by 
ion suppression or saturation, due to the wide dynamic range of the complex sample matrices 
and analyte concentrations. For example, the apparent detection of paracetamol in the 
multivitamin SRM was based on a false positive match to the [M+H-H2O]+ fragment of 
pyridoxine (Figure 3-2). Isobaric compounds  can also not be distinguished between using this 
method. Accurate mass was the primary basis of identification for this study. As discussed by 
De Vijlder, et al. 110,  the accuracy of an the isotope pattern is dependent on instrument type 
and resolving power, the mass of the ion of interest and potential inference of chemical and 
noise in the spectra. Subsequently, isotopic patterns have not been used as a primary basis 
for identification, instead the calculated pattern of the suspected compound was used to help 




Figure 3-2: DSA spectra of the NIST multivitamin SRM. The false positive match for paracetamol, [M+H]+ 152.0706 m/z, is based on the [M+H -
H2O]+ fragment of pyridoxine (also labelled as norepinephrine). The [M+H + Methanol]+ adduct of pyridoxine and [M+H]+ of pantothenic acid are 




Overall, analysis of the CAM samples confirmed the samples’ listed ingredients. For example, 
B vitamins listed as ingredients in Sample 100 were detected by this analysis. The B vitamins 
and the alkaloid trigonelline found in sample 73 were also consistent with both listed 
ingredients and the DNA data. The DSA analysis correlated well with the previous toxicological 
LC-MS screen, for example, caffeine in sample 73 was detected in both the previous and 
current analyses.  
It is important to highlight that this method does not intend to confirm the presence/absence 
or quantity of compounds within these products, but rather to serve as a rapid screening tool 
for pre- and post-market monitoring of herbal products, to give a preliminary snapshot of the 
composition. For example, the flavonoid wogonin is known to occur specifically in Scutellaria 
baicalensis 111, and its detection is in agreement with the DNA analysis of sample 175, which 
showed the product contained Scutellaria sp., as well as undeclared grass species and human 
and dog DNA contamination. We continue to advocate that a combination of mass 
spectrometry compound detection coupled with DNA analysis provides key insights into 
ingredients, substitutions and adulterations. 
The analogous results between the Ginkgo biloba samples and the NIST Ginkgo powder 
further demonstrate the potential for the DSA-TOF technique. Both the samples and the NIST 
standard contained isorhamnetin, kaempferol and quercetin, as well as other catecholamine 
and alkaloid-like compounds. While no specific Ginkgo phytochemicals were detected, the 
detection of other phytochemicals does suggest that there was plant material in the products. 
As no DNA material was detected and the previous analysis did not screen for such 




The correlation between the previous LC-MS and DNA analyses and the current DSA-TOF 
analysis, as well as the detection of non-specific plant alkaloids and flavonoids, gives strength 
to this rapid analysis for its ability to profile relevant phytochemicals and possible undeclared 
ingredients for quality control purposes. While there are limitations to this approach, DSA 
analysis allows screening of hundreds of compounds with minimal sample preparation, 
generating an outline profile of a product’s composition. For products where DNA cannot be 
extracted, or where interest in the composition is beyond a standard toxicological screen, 
such analysis can aid in a zero-tolerance approach to contaminated and adulterated products. 
Given that many regulatory agencies face the challenge of limited resources, with thousands 
of samples to be screened, but only a proportion needing comprehensive confirmation and 
quantification of possible adulterants and contaminants, DSA analysis has the potential to 
substantially improve efficiency.  
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4. Direct, high-resolution time-of-flight mass spectrometry analysis 
provides additional data for adulterated and contaminated herbal 
medicines and supplements previously analysed by LC-MS. 
 
Abstract 
Complementary and alternative medicines continue to grow in popularity in both Australia 
and overseas markets. The safety and quality of such products has been repeatedly 
questioned in numerous studies. In this study, samples previously analysed by LC-MS have 
been reanalysed using the direct sample analysis-time of flight mass spectrometry method 
previously described in this thesis. The new screening method offers minimum sample 
preparation and rapid analysis time, along with an untargeted approach to compound ID. 
Using the data from the new method combined with the previous results, 40% of samples 
were able to have at least one of the ingredients listed on the product packaging 
corroborated.  However, a further 25% of products now require further investigation to 
confirm the contents. Overall, nearly 70% of products tested now have potential adulteration 






Consumers are becoming more health conscious, with a substantial rise in ‘wellness’ trends 
and interest in ‘natural’ therapies, including complementary and alternative medicines 
(CAM). This increased use of CAM products has emphasised the current state of regulatory 
standards in many countries, finding them to be less strict with the assumption that the use 
of CAM products is ‘low-risk’ 112,113. CAM products are very popular for Australian and 
overseas consumers 87,113, yet a large proportion of these products have been found to be 
non-compliant with the current regulations 21,29,114,115.  
With many CAM products claiming efficacy for weight loss or weight/metabolism/diet 
support along with heart health, they appear attractive to the consumer who is looking to 
improve their overall health. In our recent study using a multi-tiered approach to 
pharmacovigilance with a combination of DNA metabarcoding and small molecule analysis by 
mass spectrometry, 135 CAM products (tablets, capsules, gel capsules, tea, chewable tablets 
and gummies, honey, liquids, and powder) indicated for cardiovascular health and diet issues, 
including weight loss, gastrointestinal health and metabolism support, were investigated for 
quality control issues and pharmaceutical adulteration. The study found that nearly 50% of 
products tested had contamination issues, in terms of DNA, chemical composition or both. 
Pharmaceutical adulteration and undeclared stimulants were detected in 5%, and only 21% 
of the tested products were able to have at least one ingredient corroborated by DNA 
sequencing 21. Consumers are, therefore, at risk of exposure to fraudulent, adulterated and 
contaminated products. 
All of this leads to the question that, if the label of a product does not match the contents, 
what is actually in the product? As discussed in Chapter 3 116, while useful as a confirmatory 
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method, LC-MS can be time-consuming. Detection of unknown drug analogues and novel 
compounds is also difficult using targeted methods. One approach which has the potential to 
better determine the composition of CAM products would be a rapid untargeted method. 
Generating a ‘compositional snapshot’ of a product would allow screening for 
pharmaceuticals, vitamins, phytochemicals and analogues of these compounds. Using the 
direct sample analysis-time of flight (DSA-TOF) mass spectrometer method developed 
previously 116, a subset of the original 137 samples (n = 102) were re-analysed, including a 




Full samples details can be found in Chapter 2 21. In summary, samples (n = 137) were 
purchased from various retailers and online in Australian capital cities from 2014 to 2017 and 
allocated random identification numbers. The samples existed in a variety of formulations 
(including tablets, capsules, tea, liquids and honey) and were from various origins such as 
traditional Chinese medicine (TCM), herbal medicines and supplements. Due to time 
constraints on the analysis, only a subset (n = 102) of the original 137 samples were able to 
be analysed. 
Sample preparation 
Sample preparation, extraction and analysis were the same as previously reported in Chapter 
3 116.  Briefly, samples were ground to a fine homogenised powder using a Precellys lysing kit 
consisting of CKMix 50-R 2 mL tubes (Bertin Technologies, France) and 5 mg was extracted in 
triplicate with 1 mL of methanol. Samples were then shaken for 80 s at 6500 rpm. After 
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shaking, the extracts were centrifuged for 15 min at 13.2 x 104 x g. The supernatant was 
transferred to fresh 1.5 mL tubes and dried by evaporation using an Eppendorf Concentrator 
Plus rotary vacuum concentrator (Eppendorf South Pacific Pty. Ltd., Sydney, Australia). Dry 
extracts were stored at -80°C until use. For analysis, 1 mL of 10% methanol with 0.1% formic 
acid was added to the dried extracts and the samples shaken for 10 min. 10 µL of the 
reconstituted sample was then spotted for analysis. 
DSA-TOF analysis 
DSA-TOF (PerkinElmer, Waltham, USA) conditions were as follows: positive acquisition mode, 
350°C probe temperature, 60 psi nebuliser gas (N2) pressure, 4 L/min auxiliary gas flow and 
drying gas at 3 L/min and 25°C. The corona current was 4 µA, the scan rate was 10 spectra/s, 
the capillary entrance was set to 800 V, endplate heater was 200 V, and the capillary exit was 
100 V. The total method run time was 0.55 min., with a sample spot time of 30 s. The Agilent 
APCI-L low concentration tuning mix (Agilent Technologies, Santa Clara, USA) was used to 
calibrate the DSA-TOF before analysis each day and was also used as the internal ‘lock-mass’ 
calibrant during sample acquisition. 
Data analysis 
Spectral data were viewed and analysed using AxION SOLO software, and R. Over 350 
pharmaceuticals, analogues and phytochemicals were screened against an in-house library 
(see Supplementary Table 9-3). Raw spectra were scanned by AxION SOLO for matches to 
exact monoisotopic masses and isotope ratios of targeted compounds based on the 
compound formula. The individual spectra of each sample were then processed and analysed 
in R using locally developed code (see appendix for code).  
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Results and discussion 
Figure 4-1 presents a comparison between the results for the original study (n=137) 21, and 
the cumulative results of both the original and the new DSA-TOF analysis (n=102). Detailed 
sample results can be found in Supplementary Table 9-5. 
Figure 4-1:  Evaluation of adulteration, contamination and presence of undeclared ingredients 
in CAM samples. Green is data from Chapter 2 21 only, while blue includes data from both the 
original 21 and DSA-TOF analyses combined. 
Overall, the data from the DSA-TOF analysis is in keeping with the previous findings in Chapter 
2, offering initial validation to the rapid analysis method, corroborating the results of 
adulterated products previously found. For example, paracetamol and chlorpheniramine 
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were detected in sample 296B in the original study, and the DSA-TOF analysis detected both 
paracetamol and chlorpheniramine, along with the new preliminary result of ephedrine (7.02 
ppm error). The detected of ephedrine now necessities further investigation into sample 296, 
continuing from the original LC-MS analysis in Chapter 2. 
Caffeine was the most common compound detected in both studies, found in 19% (n = 26) of 
samples in the original study and 18% (n = 18) of samples in the rapid analysis.  Synephrine 
was another common detection, but there was disagreement in the detection of synephrine 
between the two analyses. In Chapter 2, synephrine was detected in samples 24, 44, 47, 128, 
224 and 227 at concentrations of 1.1 mg/g or less. Sample 323 also contained synephrine at 
a higher concentration of 7.4 mg/g. The DSA-TOF analysis did not detect the compound in the 
majority of these samples (24, 47, 128, 224 and 227). This was most likely due to the low 
concentrations and the detection limits in complex sample matrices 116. In the case of sample 
44, the rapid analysis matched synephrine with a high mass error (> 15 ppm). The higher 
concentration in sample 323 resulted in positive detection of synephrine with a mass error of 
1.76 ppm. There were also cases where synephrine was detected in the rapid DSA-TOF 
analysis, but not found in the original study. Samples 4, 10, 59, 241, 244, 293 and 253-2 all 
had the compound tentatively identified, however, only samples 4 and 293 have ingredients 
listed that could explain the presence of synephrine. The original analysis did not detect 
synephrine in any of these samples, noting that samples 10 and 59 were unable to be analysed 
by LC-MS. The results from this study and the previous chapter 116 suggest that higher limits 
of detection and analyte volatility and polarity are limitations of the DSA-TOF method. Further 
development of the DSA-TOF method will require full validation to determine the limits of 
detection, matrix effects and analyte recovery.  
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While the original analysis focused on conventional pharmaceuticals, the DSA-TOF analysis 
screened for several phytochemicals, vitamins (such as pyridoxine, alpha-tocopherol, 
niacinamide and pantothenic acid), as well as pharmaceuticals. This extended compound 
screening helped confirm the presence of ingredients listed on the sample packaging for some 
samples by putatively identifying indicative phytochemicals. For example, in sample 218 
(which could not be analysed in the previous method) with the listed ingredients of lecithin, 
Piper nigrum and ubidecarenone, piperine, an alkaloid of the Piper nigrum (pepper) plant, 
was tentatively identified with a mass error of 5.47 ppm. Samples 77, 81 and 317 all had alpha-
tocopherol putatively identified by the DSA-TOF analysis, confirming the ingredients listed on 
the packaging. Overall, addition of the DSA-TOF data to the original data set increased the 
percentage of the samples tested that had at least one ingredient corroborated by either the 
DNA analysis or detection of an indicative phytochemical from 22% (n = 30) to 40% (n= 41)  
(Figure 4-1) 21. 
Another notable difference between the two analyses was the increased amount of positive 
data generated by the rapid DSA-TOF analysis. The cause behind this shift is the reduction in 
negative results for the toxicological analysis, where the majority of samples (74%, n = 101) 
were negative in Chapter 2. Instead, only 38% (n= 39) of samples were negative when 
screened with the DSA-TOF. 18% (n= 18) of samples had a putative compound ID which, if 
correct, indicates that further investigation is needed to confirm the product’s contents and 
if the labelled ingredients and warnings meet the current criteria. A potential limitation of the 
DSA-TOF analysis is that it is not a confirmatory method, with compounds only tentatively 
identified by accurate mass and isotopic patterns 116. This is demonstrated by the results for 
samples 6, 244 and 292, which were listed as containing Caralluma adscendens, but the DSA-
TOF analysis identified delta-9-tetrahydrocannabinol (THC) in all three samples. As the 
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samples were negative for THC in the original analysis, this result is likely a false positive for 
THC. It can be deduced that there is an interfering compound, with the same molecular weight 
as THC, present in samples containing Caralluma adscendens. The nature of this false positive 
needs further investigation.  
Applying the rapid DSA-TOF analysis developed in Chapter 3 116 to the broader sample set of 
Chapter 2 21 has offered further clarification regarding the contents of the products. 40% of 
the tested samples have had labelling claims at least partially supported by the combined 
results of DNA analysis and the DSA-TOF analysis. However, 18% of samples now require 
further investigation into their contents after the DSA-TOF analysis identified a large variety 
of compounds not explained by the product’s ingredients. When the DSA-TOF results are 
taken into consideration with the previous DNA and LC-MS results from Chapter 2, 71% of 
samples are possibly adulterated and/or contaminated. This compares to a figure of 50% 
based solely on the data from the original analysis. The results from this study further support 
our hypothesis that the contents of the products are exceedingly heterogeneous and not 
accurately reflected on the label. This chapter also demonstrates that new approaches are 
available to investigate the composition of these products and assess the risks to consumer 
safety. The DSA-TOF analysis has the potential to fill the gap between DNA and targeted 






5. The application of metabolomics for herbal medicine 
pharmacovigilance: A case study on ginseng. 
 
Crighton, E., Mullaney, I., Trengove, R., Bunce, M. & Maker, G. The application of 
metabolomics for herbal medicine pharmacovigilance: a case study on ginseng. Essays In 
Biochemistry 60, 429-435, doi:10.1042/ebc20160030 (2016). 
 
Link: 
The data in the preceding chapters has demonstrated that pre-market quality control 
measures need to be improved. Metabolomics for pharmacovigilance is a rapidly emerging 
application which can contend with the complex matrix of herbal medicines. This literature 






Herbal medicines are growing in popularity, use and commercial value; however there remain 
problems with the quality and consequently safety of these products. Adulterated, 
contaminated and fraudulent products are often found on the market, a risk compounded by 
the fact that these products are available to consumers with little or no medical advice. 
Current regulations and quality control methods are lacking in their ability to combat these 
serious problems. Metabolomics is a biochemical profiling tool that may help address these 
issues if applied to quality control of both raw ingredients and final products. Using the 
example of the popular herbal medicine, ginseng, this essay offers an overview of the 
potential use of metabolomics for quality control in herbal medicines and also highlights 
where more research is needed. 
 
Introduction: 
It has been observed by many authors that the use of complementary and alternative 
medicines (CAM) is increasing 2-5,20,29. A major component of this rise in CAM has been an 
increase in the use and commercialisation of herbal medicines. For example, sales of 
complementary medicines in Australia are currently worth a conservative estimate of A$2 
billion annually 117, while global figures for herbal medicines alone are expected to reach 
US$107 billion by 2017 29. In many countries, herbal medicines are classified under the 
regulatory guidelines for other CAM treatments, which are often ‘lightly’ regulated and largely 
based on ‘self-assessment’ by manufacturers and providers, with little to no post-market 
monitoring 6,118. As summed up by Cohen, et al. 119, “supplements are often sold as medicine, 
but regulated as food”. This type of regulation can result in a lower standard of quality and 
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efficacy assessment of the products before they are launched onto the market, due to the 
perceived low risk that is ascribed to the use of CAM 6,32. This approach can lead to numerous 
problems for consumers, health professionals and regulatory bodies, including adulteration 
with active pharmaceuticals, or the substitution of active botanical ingredients with cheaper, 
lower quality ingredients, such as rice or wheat 5,20. Contamination with heavy metals or 
pesticides is another issue which could have serious, long-term health effects 2,20,29. Despite 
these concerns, herbal medicines continue to be a popular choice for consumers, with the 
best way to regulate this industry left as a question yet to be adequately addressed. Efficacy 
arguments aside, consumers deserve access to safe, quality controlled products. The 
problems highlighted above, which are going largely unchecked by the industry, demonstrate 
a compelling need to research more effective methods of quality control, both in terms of the 
methods utilised, and the overall system. The scope of this essay seeks to summarise the 
potential of metabolomics in the regulation of the herbal medicine sector. We refer readers 
to other review articles for descriptions of instrumentation and methodologies 120-122   
Formulations classed as ‘herbal medicines’ are variable, ranging from single plant products, 
such as ginseng, Echinacea or St. John’s wort (Hypericum perforatum), to complex, multiple 
ingredient products, such as those used in traditional Chinese medicine (TCM). Most products 
on the large international commercial market are standardised based on the anticipated 
bioactive components of botanical ingredients, such as hypericin in St. John’s wort 123. In other 
cases, extracts are normalised to the quantity of the dry herb which they contain 124. However, 
when the bioactive component of a herbal medicine is unknown, or there are multiple 
possible active compounds (such as the ginsenosides found in ginseng), quality control 
becomes a far more complex problem. This complexity increases further when multiple 
ingredient products, each with their own bioactive components and mechanisms of action, 
82 
 
are considered. The chain of production is another important factor, as growing conditions, 
time of day and year when the plant was harvested, storage conditions, extraction process 
and the formulation used in the final preparation can all affect the bioactive compounds 
present, both in terms of composition and concentration 123-125.  
Current, and arguably inadequate, quality control procedures utilise various methods, 
including plant morphology 126,127, chemical analysis 128,129 and DNA assays 127. In some cases, 
a pharmacopoeia monograph may exist for a single, specific herbal medicine and outline the 
expected quality parameters, such as morphological tests, chromatography profiles and 
quantified tests for active ingredients 130. In cases where a monograph does not exist, quality 
control methods are open to interpretation and potential bias. Even when monographs are 
available, they are often out-dated or limited. For example, there may be a monograph for 
the raw plant but not an extracted form. Plant morphology is difficult, particularly when 
dealing with dried or processed material, or only specific parts of a plant 131. Such techniques 
often lack the specificity required to differentiate closely related species with similar features. 
Chromatographic profiles, or fingerprints, can be used for plant identification and can 
quantify suspected active ingredients. However, these profiles rely on phytochemicals that 
have been previously identified and the availability of reference compounds or herbal 
medicine/ botanical reference standards for comparison. In cases where there are limited 
studies on the phytochemical composition of a particular herbal medicine, the lack of data 
will greatly restrict the utility of chromatographic analysis 131,132. The use of chromatographic 
fingerprinting also does not account for different experimental conditions and cannot be used 
to compare between plant species, growing locations and conditions, harvesting times and 
methods, or different extraction processes 129. DNA barcoding has been successful in 
identifying the presence of endangered species, product substitution and the use of 
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dangerous or toxic plants, but there are limits to this single approach. Degradation of DNA 
during processing of products is a significant problem, and detection of DNA from a toxic or 
bioactive plant species does not indicate the presence of the toxic or bioactive components 
of that plant 3,20. 
Recently, the growing technology of metabolomics has been proposed as part of the solution 
to the current limitations surrounding herbal medicine quality control and safety 129. A 
domain of the ‘omics group of technologies, metabolomics has been widely employed for 
drug discovery, identification of biomarkers of disease 133,134 and studies of animal and plant 
biochemistry and toxicology 125,135-137. Metabolomics allows the identification and 
quantification of the small molecule metabolites within a given sample and therefore 
provides a detailed insight into the biochemical composition of that sample. Metabolomics 
can be considered as essentially providing a ‘snapshot’ of the biochemistry at a given time 
and under specific conditions. This systematic approach allows for change to be observed and 
distinguished under different conditions, such as disease state, stress conditions and seasonal 
variations 125,129,135,137. Plant metabolomics has been successfully used to distinguish between 
plant parts 138, age 139 and species 126,135, processed and unprocessed products 125, and also 
different regions of cultivation 140,141.  
To highlight the possible use of metabolomics for quality control in herbal medicines, its 
application to the popular herbal medicine ginseng will be discussed. Several studies will be 
considered as an example of what can be achieved using metabolomics, and to emphasise 
what further development is needed across the herbal medicine sector. 
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Ginseng and metabolomics: 
Ginseng has been used for over 2000 years, with current production estimated at 8000 tons 
per year and a global market of approximately US$2 billion 135. Quality control factors of 
primary concern, such as species composition, region of origin and methods of processing, 
have all been assessed using metabolomic analysis of ginseng, making it an excellent case 
study of the potential applicability of metabolomics in quality control of herbal medicines in 
general.  
Herbal products labelled as ‘ginseng’ are usually the root of the Panax species, including 
Panax ginseng C. A. Meyer (Asian or Korean ginseng), P. japonicus (Japanese ginseng) and P. 
quinquefolius L. (American ginseng) 126,142. P. notoginseng is another species which also 
contains many of the same active ginsenosides 143. The bioactive components of ginseng are 
numerous, including polysaccharides, saponins, polyacetylenes, sesquiterpenes and fatty 
acids 140,142. However, the dammarane saponins, more commonly known as ginsenosides 141 
have been attributed to most of the possible therapeutic effects of the plant 139,140. More than 
40 ginsenosides have been identified from the root of P. ginseng 139,140, with reported 
therapeutic effects including antioxidant, anti-tumor, immunostimulatory, anti-
hyperglycaemic 126, anti-aging, vasodilatory, and memory enhancement effects 141. It is due 
to its continued popularity, considerable market size and value, and numerous possible 
pharmacological effects that fraudulent ginseng products are a notable problem 125,141. 
Particular issues include fraudulent declaration of the area of cultivation and the ‘blending’ 
of wild-type ginseng with  the cheaper alternatives; both of which are associated with a lower 
cost or pharmacological effects 141. 
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Zhao, et al. 126 compared commercially sourced P. ginseng and both wild and cultivated P. 
quinquefolius and found that sugar (glucose vs. sucrose) content was a major difference 
between species. When sugars were excluded from the principal component analysis (PCA), 
P. ginseng was shown to contain significantly higher levels of arginine, choline, malate and 2-
oxoglutarate than both types of P. quinquefolius (P < 0.01). A downside to this study, as noted 
by the authors, is that these samples were commercially purchased. As such, factors which 
would affect the metabolite composition, such as the age and cultivation of the samples, 
could not be controlled. Despite this, not only was the 1H NMR metabolomic analysis was 
successful at distinguishing the three types of ginseng analysed, with three distinct metabolite 
profiles generated. A sample claiming to be cultivated P. quinquefolius was found to have a 
different profile from all other sample types. This suggests that an inferior plant with less 
commercial value may have been sold as a substitute for cultivated P. quinquefolius. 
Nguyen, et al. 141 compared a metabolomic approach to a DNA-based approach using 
chloroplast intergenic space regions for distinguishing area of cultivation of P. ginseng. They 
found that all sixty ginseng samples had very little genetic diversity between cultivation 
regions 141, whereas the metabolomic approach was effective at distinguishing between 
cultivation regions in Korea and China. It was hypothesised that changes in the concentration 
of carbohydrates and other metabolites involved in energy generation pathways are distinct 
based on the different environmental stresses and cultivation conditions between Korea and 
China. Notably, the change in harvesting time from before winter (Korea) to after winter 
(China) resulted in a change in carbohydrate levels, with higher levels of the primary 
metabolites detected in the Korean samples 141. In identifying these changing metabolites, 
their respective biochemical pathways, and how they interact with the environment, both 
growing conditions and harvesting methods may be further optimised 141. The authors also 
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constructed a statistical model to predict the ratio between blends of ginseng from the 
different regions, using a constrained least squares method. The model was modestly 
accurate at estimating the percentage amounts of Korean ginseng in a blend when compared 
to the known true amount (R2 of 0.8343). The ability to provenance herbal products based on 
metabolomics profiles is a promising area of research that warrants further investigation. 
It has been established that processing and extraction of plant material alters the composition 
of the final medicinal product 124,125. A metabolomic study conducted by Chan, et al. 125 using 
ultra-performance liquid chromatography coupled to time-of-flight mass spectrometry 
(UPLC-TOF-MS) sought to measure biochemical differences, in particular ginsenoside content, 
between raw and steamed P. notoginseng root. There was a large variation in the metabolite 
profiles of the raw extracts, even though all samples were extracted in the same manner. The 
steamed extracts showed a much smaller level of variation, suggesting that the steaming 
process may, in altering the biochemical composition, result in a greater consistency in the 
final product. Chan, et al. 125 detected approximately 200 metabolites in raw and steamed P. 
notoginseng root and attempted to identify possible biomarkers for each processing 
technique. This aspect of the study was limited by the small sample size (n=6), but did 
demonstrate the potential of metabolomics to identify differently processed botanical 
material.  
Another potential quality control factor that has been investigated using metabolomics is the 
age of the plant at the time of harvesting, with older plants being higher in value and market 
demand 139. Kim, et al. 139, analysed P. ginseng root with cultivation ages of one to six years. 
Using UPLC-TOF-MS, 1361 metabolites were identified from sixty P. ginseng samples. Despite 
few chromatographic differences, the ginseng samples were able to be grouped by age using 
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the identified metabolites. The metabolite selection was based on several classification 
methods: random forest, prediction analysis of microarray, and partial least squares 
discriminant analysis 139. With this selective approach, age discrimination was achieved, 
particularly of the older ginseng root (> 4 years). 
The studies outlined above have shown that metabolomics is a potentially powerful tool in 
addressing numerous quality control issues for herbal medicines, being able to distinguish 
between species, age and areas of cultivations, with a substitute product identified in one 
study 126. In addition, the methods can be rapid and high-throughput (>1000 samples per day) 
144, critical advantages when dealing with a high volume of samples. One such high-
throughput approach is as the rapid evaporative ionisation mass spectrometry (REIMS) 
technology, which has recently been applied to investigation of authenticity and fraud in meat 
products 145.  
Moving forward: 
The purpose of this review is to demonstrate whether metabolomics can be an effective tool 
for the quality control of herbal medicines. Metabolomics clearly has the potential to improve 
numerous aspects of the pipeline used in the herbal medicine industry, and data collected to 
date has demonstrated that a deeper look into the biochemistry of the botanical ingredients 
needs to be a strong focus of future research. The question then becomes whether 
metabolomics is a better, more rigorous test for quality compared to the current methods, 
such as monographs, or if it is likely to remain a secondary tool. Current methods of quality 
control can become out-of-date as more is learned about the botanical ingredients of herbal 
medicines. For example, in the case of St. John’s wort where, as mentioned above, the extract 
if often standardised based on the amount of hypericin. Recent findings now suggest that 
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there are numerous other active compounds in the plant 146, none of which are covered by 
the existing quality control approach. This demonstrates that methods using a single 
compound as a standard are no longer appropriate.  
There any many advantages to the ‘top-down’ approach of metabolomics; the most notable 
one being that metabolomics is the closest measurement to a system’s phenotype 147. In the 
case of untargeted metabolomics, another advantage is that retrospective data analysis is 
possible; allowing for data to be re-analysed for a different purpose (such as biomarker 
identification or metabolite fingerprinting) without the need to re-analyse a sample. 
However, metabolomics is not without potential limitations, and these have been thoroughly 
reviewed 120,122,148,149. Multiple platforms such as gas chromatography-mass spectrometry, 
liquid chromatography-mass spectrometry, and nuclear magnetic resonance spectroscopy 
are needed to cover the broad range of chemical properties of possible analytes 139. While 
this range could be overcome with advances in the technology platforms, being certain of the 
identification of the analytes is another matter 122,148. The most assured method of 
identification is comparison with an authentic standard under the same experimental 
conditions, as used by Gao, et al. 131. However, such comparison may not always be possible, 
in which case the confidence of analyte identification needs to be made clear based on a 
systematic scoring system 148. The studies summarised above are promising initial steps, but 
there needs to a concerted effort to comprehensively compare the metabolite profiles of the 
many plants used in herbal medicines. A limitation of the studies considered above is the fact 
that analysis is often limited to a subset of the metabolites present, as identified by 
multivariate analysis of the data. Many studies have focused only on the possible major active 
phytochemicals, in this case ginsenosides, which limits the power of metabolomics. 
Exceptions to this narrow focus include the studies by Kim, et al. 139 and Nguyen, et al. 141.  
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Another limitation is the data analysis methods that have been applied. While PCA and other 
multivariate statistical methods such as hierarchical clustering analysis are acceptable for 
pattern recognition and determining the major components that result in sample variability, 
digging further into the biochemical composition of herbal medicines is crucial 131. The use of 
metabolomics for the optimisation of the production chain could allow producers to achieve 
the best quality plants for commercial purposes, by determining which combination of 
conditions will produce the best yield of high-quality components in particular species 123,124. 
This approach would also generate a deeper understanding of the botanical ingredients, 
which will allow for more comprehensive and guided quality control of the final products. To 
know exactly which metabolites, and therefore possible active phytochemicals, are 
responsible for variation in the herbal medicine of interest would be invaluable, potentially 
providing novel biomarkers for quality control 131, and allowing properly-designed evidence-
based efficacy studies of herbal medicines or identifying putative pharmacologically active 
compounds. This use of metabolomics to map the underlying biology of botanical ingredients 
goes beyond routine quality control and approaches the more comprehensive techniques 
used in pharmaceutical discovery and development.  It is worth noting that the application of 
pharmacometabolomics and toxicometabolomics for studies on the bioactivity of herbal 
medicines is another area where ‘omics shows great promise 150-152. 
One proposed solution to the issue of quality control, beyond the utilisation of good 
manufacturing practices (GMP), is for a combined DNA and metabolomic testing approach. 
Such an approach is needed for the simple reason the intentional adulteration is not avoided 
by GMP alone 153.  This combined approach, similar to the one presented in Coghlan, et al. 20, 
would involve the use of DNA barcoding and mass spectrometry to screen for adulterants and 
contaminants, and metabolomics to scrutinise quality and safety. This combined approach 
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must be applied to both raw ingredients and final quality checks of market-ready products 132 
to ensure that processing methods do not reduce the quality and content of desired 
phytochemicals. Continuous regulatory assessment of post-market products should also be 
implemented to provide higher quality commercial products. The added benefits of such 
rigorous testing, including the involvement of regulatory evaluation and possible third-party 
analysis is that the issues of contamination and adulteration can also be confronted without 
the reliance on a trust-based industry system. The set up costs associated with metabolomics 
and mass spectrometry would surely be offset by the benefits to health systems 13. A key next 
step will be to undertake comparative research on traditional quality control methods and 
metabolomics 135. 
Conclusion: 
To improve compliance and safety, and therefore public confidence, the herbal medicine 
industry needs new processes for sufficient and effective quality control. The numerous 
reports of adulterated, contaminated and fraudulent products have demonstrated this need 
for change. Metabolomics has the potential to offer a solution to many of the quality control 
problems with herbal medicines. As demonstrated above, metabolomics can effectively 
determine product pipeline changes, including differences in regional cultivation, and 
distinguish between plant species and age, processing methods and blended products. A 
combined -omics’ approach with DNA testing would move further to build a new standard of 
testing. However, as outlined above, further research into the biochemistry of the numerous 
ingredients in herbal medicines is clearly needed. It is an ambitious undertaking to develop 
high-fedelity and cost-effective –omics’ toolkit, but the approach offers an  pathway to 









6. Metabolomic analysis of commercially purchased herbal products 
(green tea and Korean ginseng) to assess quality and safety. 
 
Link: 
Following on from the review in Chapter 5, an untargeted GC-MS metabolomics workflow was 
employed to compare the compositional diversity of green tea and Korean ginseng products. 
Linking with the DSA screening method developed in Chapters 3 and 4, where 18% of samples 
now require further investigation into their contents due to the large variety of unidentified 
compounds detected, metabolite profiling would allow comparison to standard reference 
materials. This may possibly lead to new quality and safety control methods for these complex 
matrices. Green tea and Korean ginseng products were chosen due to the overall popularity 




The use of herbal medicines is growing throughout the world, with various levels of regulation 
in place. Raw plant ingredients are known to change in biochemical composition based on 
growth conditions, extraction and processing. The compositional diversity of finished 
products is not, however, routinely assessed in many countries. Using an untargeted 
metabolomics approach, green tea and Korean ginseng commercial products, purchased 
between 2015 and 2017, were analysed by GC-MS and compared to standard reference 
materials. The green tea products showed significant compositional differences, both from 
each other and the reference standard, while the ginseng products showed large intra-sample 
variation. The analysis showed that, despite all products stating the same ingredients, there 
was a clear difference in biochemical profile between products and the reference materials. 
 
Introduction 
Herbal medicines are becoming increasing popular throughout the world 154. From use as 
primary health care and folk medicines to commercial and highly marketed products, herbal 
medicines can range from simple single ingredient teas to complex, multi-ingredient extracts 
and pills. The higher the complexity in the ingredients and formulation of a product, the more 
difficult it is to ensure quantity and safety. Factors in herbal medicine quality control include 
longer production chains for commercial products, issues with plant morphological 
identification, use of substitute and filler ingredients, adulteration and contamination of both 
raw and final products, batch to batch variation, and the natural variation of phytochemicals 
affecting the potential bioactive constituents. Despite the many factors that affect the final 
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composition of a product, quality control measures often rely on single content assays and 
standardisation to potential bioactive constituents (e.g., ginsenosides in Panax ginseng).  
Recently, a more comprehensive approach to the characterisation of herbal products has 
been taken using metabolomics 152,155-158. The advantage of such an approach is that many of 
the factors affecting composition such as plant age 139, growth conditions 156, processed and 
raw material 141, the use of fillers and species substitution 141,159,160 can be identified. Beyond 
quality control applications, metabolite profiling of herbal medicines has been of increasing 
interest 124,152,158,160 for potential outcomes in identifying active phytochemicals and 
optimisation of the production chain for commercial plant products. Metabolomics for 
comparison of compositional diversity has been applied to several herbal products such as St. 
John’s wort 123,159 and chamomile tea 161.  Metabolomics and chemometrics have also been 
used to discriminate counterfeit medicines and authenticate raw herbal materials 141,162,163 
with varied success. 
Green tea and ginseng are some of the most popular herbal medicines used today 141,164. 
Ginseng has been used a medical herb for over 2000 years with Panax ginseng, also known as 
Korean ginseng, one of the most commonly used herbal medicines 135,141, for its professed 
strengthening and rejuvenating powers 165. There are numerous bioactive components of 
ginseng, with the group of dammarane saponins or ginsenosides exhibiting numerous 
pharmacological effects including antioxidant, immunostimulatory 126, vasodilatory, and 
memory enhancement effects 141.  Green tea, Camellia sinensis, is also a popular medicinal 
herb and one of the most popular drinks worldwide, second only to water 166, and an 
increasingly popular weight-loss supplement 167. Components of green tea such as the 
polyphenols, including the catechins and gallic acid, have been shown to exhibit antioxidant 
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activity 166. Epigallocatechin gallate (EGCG) is thought to have a variety of beneficial effects 
168, but has also been implicated in liver and kidney toxicity, particularly when taken in the 
high doses found in ‘green tea extract’ products 167.  
A better understanding of the compositional variation of products will allow us to better 
assess the safety and quality of these products. This study used an untargeted metabolomic 
workflow and multivariate data analysis to assess the composition of commercial single 
ingredient herbal products (green tea and Korean ginseng) on the Australian market. 
Method 
Materials and sample details 
LC-MS grade methanol and water were purchased from Fisher Scientific (Hampton, USA). D- 
13C6-sorbitol (internal standard), methoxyamine hydrochloride, n-alkanes (C10, C12, C15, C19, 
C22, C28, C32, C36), N-methyl-N-(trimethylsilyl) trifluoroacetamide (MSTFA) and pyridine were 
all purchased from Sigma-Aldrich in the highest purity available. CAM and herbal medicine 
(HM) products labelled to contain green tea (GT) (n = 5) or Korean ginseng (KG) (n = 7) were 
purchased between 2015 and 2017 from various Australian retailers (Table 6-1). NIST 
standard reference material (SRM) Camellia sinensis (GT) (SRM 3254) and European 





Table 6-1: Stated ingredients and indications of herbal medicines (HM) and CAM samples 










Indications on package 
Korean 
ginseng 
HM_6 Y Panax ginseng Enhances stamina and endurance, supports 
energy levels, reduces fatigue, enhances 
concentration and work efficiency, helps with 





HM_7 Y Panax ginseng Help promote general endurance and assist 
stamina. Best used in times of physical exertion. 
Aid in the maintenance of general wellbeing. 
HM_8 Y Panax ginseng Increase stamina, endurance and vitality. Relieve 
nervous tension and stress, support busy, active 
lifestyles. 
HM_9 Y Panax ginseng 
root powder 
Helps to improve stamina and endurance, may be 
beneficial during times of stress, helps to 
maintain the immune system. 
HM_10 Y Panax ginseng  Energise and invigorate the body. Strengthen the 
immune system. Improve physical performance, 
endurance, stamina and fitness. Of benefit during 
times of stress. 





HM_18 Y Panax ginseng 
root extract 
May assist in maintaining general well-being and 
help to provide increased endurance. 
Green 
tea 
HM_19 Y Camellia sinensis, 
Coffea canephora 
Aids healthy weight loss. May help people who’ve 
lost weight avoid putting it back on. Activates 
thermogenesis. Supports heart and blood vessel 
health. Helps neutralise potentially damaging free 
radicals. 
 
HM_20 Y Camellia sinensis Assist with healthy weight management. Help to 
maintain healthy body weight. Enhance the 
body’s antioxidant defences. Increase energy and 
promote detoxification. Maintain normal health 












Indications on package 
CAM_239 Y Camellia sinensis, 
Coffea canephora 
Helps burn fat and supports healthy weight loss. 
Activates thermogenesis to help burn stored fat 
for energy. Helps improve body composition and 
reduce body fat percentage and body mass index 
(BMI). Supports normal burning of calories for fat 
loss and assists in maintaining healthy metabolic 
function. Helps regulate absorption and 
utilisation of glucose and fat from the diet. May 
also assist weight loss by supporting normal 
glucose metabolism and blood sugar levels in 
healthy individuals. May reduce the oxidation of 













2 in 1 Slimming and Detox. Strong antioxidant 
formula. 
CAM_305 Y Camellia sinensis Provide antioxidant support, cardiovascular 
health, healthy metabolism. 
 
Sample preparation and extraction 
10 tablets or tea bags from each product were ground to a fine homogenised powder using 
Precellys CKMix 50-R 2 mL lysing tubes (Bertin Technologies, France). The NIST SRM GT 
product was sampled twice, with one set being brewed for extraction. Powdered samples 
were transferred to 2 mL lysis tubes and stored at -80°C until use. Approximately 5 mg of each 
sample was extracted multiple times with methanol and water. The first extraction used 0.5 
mL methanol containing 13C6-sorbitol internal standard (1.11 µg/mL). The samples were 
shaken for 40 s at 6500 rpm in the Precellys tissue lyser. After shaking, extracts were 
centrifuged for 10 min at 13.2 x 104 x g and 0.35 mL of supernatant was collected. Samples 
were then extracted again with 0.5 mL of methanol and shaken and centrifuged as above, 
with 0.4 mL of supernatant collected. The final extraction was 0.5 mL of 50% methanol, 
shaken and centrifuged as above, with 0.45 mL of supernatant collected.  
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To brew the tea samples (CAM_245), 5 mg of ground tea was prepared with 1 mL of water, 
heated to 95°C and shaken at 400 rpm for 10 min. The tea was then centrifuged for 10 min at 
13.2 x 104 x g and 0.9 mL of supernatant was collected and dried by evaporation using an 
Eppendorf Concentrator Plus rotary vacuum concentrator (Eppendorf South Pacific Pty. Ltd., 
Sydney, Australia). The brewed tea was then triple extracted as described above.  
QC samples were made from a pooled sample of the extracts. Extracts were diluted 1:10 and 
dried by evaporation in vial inserts. Dry extracts (both neat and 1:10) were stored at -80°C 
until derivatisation. Derivatisation was carried out by treating the freeze-dried extracts with 
20 µl of methoxyamine hydrochloride solution (20 mg/ml in pyridine) and agitated using an 
Eppendorf Thermomixer Comfort at 1200 rpm and 30°C for 90 min. Extracts were then 
centrifuged for 1 min at 13.2 x 104 x g. 40 µl of N-methyl-N-(trimethylsilyl) trifluoroacetamide 
(MSTFA) was added and the extracts were further agitated for 30 min at 300 rpm at 75°C. 5 
µl of alkanes in n-hexane was added and samples were centrifuged for 1 min at 13.2 x 104 x g 
for a final time before analysis within 12 h. The GT and KG samples were analysed separately 
with only the 1:10 dilutions being analysed.  
GC-QTOF instrumentation  
An Agilent 7200 QTOF-GC-MS (Agilent Technologies, Santa Clara, USA) was used for 
untargeted metabolomic analysis with electron ionisation. 1 µL of derivatised sample was 
injected into the inlet at 270°C in splitless mode, with the carrier gas of ultra-high purity 
helium at a constant flow rate of 0.85 mL/min. An Agilent VF-5-ms fused silica capillary column 
was used (0.25 mm ID, 30 m length, 0.25 µm film, and 10 m EZ-guard). The chromatographic 
method was 23.5 min and included a 10-min solvent delay. Initial oven temperature was 70°C 
before a temperature ramp of 15°C/min for 6 min and 40 s until the final temperature of 
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325°C was reached. The transfer line was set at 300°C and the ion source to 280°C. Ionisation 
was achieved with a 70 eV electron beam. The MS has a scan rate of 10 spectral scans/s and 
scanned ion masses in the range of m/z 50 to 700. For both sample sets, samples were 
randomised and the run sequence started with three extraction blanks, then eight QC samples 
for conditioning. A QC sample was included every sixth injection, as well as at the start and 
end of the derivatisation batches. 
Data analysis and statistics 
GC-MS data was processed and deconvoluted using AnalyzerPro v5.5.1, (SpectralWorks, 
Runcorn, UK). Data pre-treatment included zero-filling using MetImp 169, with 50% filtering of 
missing values and random forest (RF) imputation applied. Further data treatment and 
statistical analysis of the data matrix was carried out using MetaboAnalyst 170, with filtering 
(RSD >30% based on QC samples), cube root or log transformation (for the GT and KG data 
sets, respectively) and quantile normalisation carried out. The principal component analysis 
(PCA) and heatmaps were generated by MetaboAnalyst while EZInfo, v3.0 (Umetrics) was 
used for ANOVA comparisons between sample groups. 
Results 
Green tea 
Overall, 1301 components were detected over the analysis of the five different GT products 
and SRM. After filtering and processing, 84 components (noted as M_1 to 84) were imported 
into MetaboAnalyst. The GT group comprised of three distinct product types: green tea 
tablets (n=2), green tea + green coffee tablets (n=2) and green tea leaves , sample CAM_245/ 
B_245 (n=1, raw vs brewed).  
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Figure 6-1 shows the PCA scores plot for all of the green tea products analysed compared to 
the SRM, with the different samples types then compared separately. All of these 
comparisons (Figures 6-2 to 6-4) show that samples of the same product type group together, 
but separate from the SRM. This may be expected for samples containing green tea + green 
coffee (Figure 6-2), but is more surprising for green tea tablets (Figure 6-3) and green tea 
leaves (Figure 6-4), which would be expected to be more similar to the SRM. Figure 4 also 
shows that raw and brewed tea leaves had similar metabolic profiles. Figure 6-5 comprises 
the group means for the top 25 components. The difference between samples and the SRM 
is most prominent for components M_28, M_40, M_54, M_49, M_68 and M_20. These 
components are also responsible for the separation of the groups on the PCA. The 
concentration of these components are also responsible for the disbursement seen in some 
of the samples replicates. For example, M_28 and M_40 are responsible for the wide scatter 





Figure 6-1: PCA scores plot of GC-MS data from all GT products and the NIST reference 
standard. 
 
Figure 6-2: PCA scores plot of GC-MS data from green tea + green coffee products 




Figure 6-3: PCA scores plot of GC-MS data from green tea tablet products (CAM_305 and 
HM_20) compared to the NIST reference standard.  
 
Figure 6-4: PCA scores plot of GC-MS data from green tea leaves, raw (CAM_245) and brewed 




Figure 6-5: Heatmap of the group means for the top 25 components as determined by PCA 
between all samples. 
 
Ginseng 
For KG, 2126 components were detected for the analysis of seven Panax ginseng samples and 
the reference standard. After filtering and processing, 103 components were imported into 
MetaboAnalyst. Four sample replicates were removed as outliers based on RF and not 
included in the PCA or heatmap analysis. HM samples 6 to 10 were tablets or capsules, HM11 
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was a ginseng tea and HM18 was a liquid sample. The products were stated to be standardised 
by either ginsenoside content or the amount of dried ginseng in the extract. Due to the same 
single ingredient, samples would be expected to be similar, as reflected in Figure 6-6, which 
shows the PCA scores plot for all of the ginseng products analysed. However, there is a large 
variation within the KG sample groups and separation of the reference standard from the 
majority of the samples. When compared using a heatmap (Figure 6-7), there are a number 
of components with significant difference (p < 0.001) which correlate to the PCA separation; 
M_2078, M_2078, M_1181, M_2046, M_460 and M_1146. 
 
 
Figure 6-6: PCA scores plot of GC-MS data from KG products and the European 




Figure 6-7: Heatmap of the group means for the top 25 components identified by PCA of all 
Panax ginseng samples. 
 
Discussion  
The key observation from this study is the variation within, and between, sample groups and 
corresponding reference standard. All products tested showed significant compositional 
differences, both from each other and the reference standards. While some of this diversity 
is likely due to different processing methods between brands and products, the reference 
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standard in both sample sets was distinct in the PCA analysis. This indicates that the 
composition of the products varied, even though they all contained the same ingredient. 
Currently in Australia, only pre-approved ingredients which have been deemed low risk are 
allowed to be marketed and sold 34. With such compositional diversity, even when the 
products contain the same ingredient (as per the label), the difference between pre-approval 
of ingredients and pre-approval of an individual product becomes crucial to assessing a 
product’s safety. Assuming that the diversity observed is from the advertised ingredient, 
there are a multitude of factors that would affect the final chemical composition of a herbal 
product. All stages of production will affect the biochemical profile of a herbal product, from 
the growth conditions of the plants, to the harvesting, storage and processing of raw 
materials, extraction of potential active ingredients and production of the final product, 124,171, 
as reviewed in Chapter 5. 
Green tea is an increasingly popular weight loss supplement, with all products tested having 
indications such as ‘weight management or loss, detox, and metabolism support’ (Figure 6-1). 
Green tea products indicated for weight loss have been linked to liver damage in several case 
studies 167,168,172,173. The major compounds of green tea attributed to the bioactivity are 
catechins 166 with the most abundant, epigallocatechin gallate, along with caffeine, thought 
to account for the potential weight loss effects 164. A 2012 Cochrane review found green tea 
had no significant effect on weight maintenance 164. Figure 6-3 shows how distinctly different 
the green tea tablets (CAM_305 and HM_20) were to the NIST SRM in terms of GC-MS profile. 
Figure 6-4 shows a similar separation between the SRM and green tea leaves, raw or brewed. 
Such compositional differences between products and the SRM raise the question of how 
representative SRMs are to the marketed products, as well as the usefulness of such 
standards for QC. Furthermore, with such diversity, large variation of the potential 
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pharmacologically active compounds, such as catechins, cannot be ruled out. It was noted by 
Jurgens, et al. 164 that inconsistency in product content may account for the variation in results 
obtained in the systematic Cochrane review. To challenge this inconsistency and variation in 
products, quality control techniques must move beyond quantifying only the known or 
suspected active compound. By profiling the complete composition of raw and processed 
ingredients and finished products, reliable and consistent herbal products can hopefully be 
produced 154,159,174,175.  
Unlike the GT analysis, the KG products showed greater similarly to the reference standard 
(Figure 6-6), although there was a larger variation within sample replicates compared to the 
reference standard. Ginsenosides are the attributed active compounds for the Panax species, 
and products are often standardised by ginsenoside content. However, with over 40 
ginsenosides identified from the root of Panax ginseng 140, standardising to the vague 
description of ‘ginsenosides’ does not reveal much about the total composition of a product. 
The products analysed fell into two groups: standardised to ginsenoside content or 
standardised to amount of dried product in the extract. 
As previously reviewed in Chapter 5 171, there have been numerous studies into the use of 
metabolomics in characterising quality control factors such as species, age and region of origin 
for raw ingredients. In this study, the different standardisation methods and known variation 
in raw ingredients did not translate into large variability between sample groups in the PCA 
(Figure 6-6 and Figure 6-8), although there were still components that were significantly 
different (p < 0.001) (Figure 6-7). Contrasting the KG data with the GT results, the ginseng 
reference standard appears to be more representative of commercial products, which could 





Figure 6-8: PCA scores plot of GC-MS data from KG products based on the standardisation 
methods: ginsenoside content (GC) or standardised to amount of dried product (DC). The 
amounts ranged from 4 mg to over 40 mg of ginsenosides or 400 mg to 2 g of dry ginseng. 
 
Three of the samples had been analysed in our previous study by DNA barcoding and LC-MS 
analysis 116. Samples CAM 239, 245 and 305 all contained caffeine. Of the samples not 
previously analysed, the green tea + green coffee tablets (HM_19) and green tea tablets 
(HM_20) also declared caffeine content on the product labels. CAM 245 was found to have 
animal contamination (dog, camel and ox) and additional animal DNA (frog and Asian highland 
shrew) and CAM 305 also contained additional plant DNA (Apiaceae sp.). Further work is 
needed to better characterise the chemical components of these products to determine if the 
109 
 
diversity encountered in this study arose from the declared ingredients, the formulation or 
undeclared botanicals and contaminants.  
The key next step in this research is the extensive process of identifying these components. 
Approaches to identifying components include comparison to in-house libraries of authentic 
standards where available or searching against publicly accessible spectra libraries and 
databases. However, due to incompleteness of libraries, matrix background and noise, these 
approaches do not always lead to structural identification of the compounds of interest 176.  
Structure elucidation of small molecules requires excellent mass accuracy for chemical 
formula computation alone, often leaving many possible compound formula matches to 
components at the higher masses ranges 177,178. Currently levels or scoring systems are used 
to assess putative identification, with comparison to authentic standards at the highest level, 
and fragmentation pattern analysis, isotopic patterns and accurate mass scoring lower 148.  
Conclusion 
This study presents a potential new approach to understanding herbal product composition 
using metabolomics. The results from this study and others 123,141,159,161 show that, 
notwithstanding the use of standardised methods such as ginsenoside content, there is still 
large compositional diversity among finished herbal products on the market. What is still 
unclear is whether this compositional diversity has any safety implications, with unknown 
bioactive phytochemicals possibly accounting for the variation. The use of metabolomics and 
similar techniques to screen for adulterated and fraudulent products is one which needs 
further research and time, but approaches that allow the full chemical composition of a herbal 
product are clearly needed to produce more consistent and safer products.  
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7. General discussion 
 
The first part of this thesis, Chapters 1 to 4, investigated methods for detection of 
adulteration/contamination in CAM products, and used these methods to examine the 
occurrence of such issues. Chapter 2 showed that 50% of samples indicated for diet, 
cardiovascular health and general wellness/wellbeing contained undeclared ingredients. The 
original research presented in Chapter 2 is part of a larger body of work studying the quality 
of CAM products available on the Australian market 89,179 (manuscripts included in the 
Appendix).  Hoban, et al. 89 details the testing of a further 59 products indicated for psychiatric 
conditions such as insomnia or sleeplessness, anxiety and depression, finding that 29 products 
(49%) contained substances not declared as listed ingredients. This included heavy metals 
such as lead and cadmium at levels above the TGA guidelines 89. For 49 products indicated for 
analgesic and anti-inflammatory use, 26 (53%) were adulterated or contaminated with 
undeclared ingredients 179. Combined, these studies suggest that, despite the different 
indications, the level of undeclared ingredients remains mostly consistent at approximately 
50%.   
The individual methods employed in this research are not novel for testing CAM and herbal 
medicine product. As reviewed in Chapter 1, there are numerous LC-MS methods for the 
targeted screening of pharmaceuticals in herbal matrices, including high resolution LC-MS 
methods such as those employed by Jin, et al. 180 and Guo, et al. 181. However, the novel 
combination of the techniques of DNA barcoding and LC-MS analysis has provided a more 
comprehensive picture on a product’s contents, allowing the ingredient claims to be 
ascertained, as demonstrated in Chapter 2. However, in spite of the scope of data obtained, 
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there is not one universal method for quality control for complex products. Questions can 
remain regarding the total content and compositions of products, particularly when only 
targeted analysis has been carried out.  
Chapters 3 and 4 detail the development and application of the DSA-TOF, a rapid and direct 
sampling MS screening method. This method, while not as comprehensive as LC-MS analysis, 
was able to screen for the majority of a selection of pharmaceuticals in an analysis time of 
less than one minute.  Applying the method in Chapter 4, 18% of samples had a variety of 
unidentified compounds detected and require further investigation into their contents. When 
the results were combined with those from Chapter 2, 71% of samples tested were either 
adulterated or contaminated. Only 40% of the tested samples had their labelling claims 
somewhat substantiated by the combined results of the different analyses. 
Following on from the questions raised in the first part of the thesis, the second part of this 
thesis was concerned with the content and composition of herbal products on the Australian 
market and how untargeted metabolomics can be used for as a quality control technique. 
Chapters 5 and 6 focused on single ingredient herbal products, reviewing and applying 
metabolomics and metabolite profiling to green tea and Korean ginseng CAM products. As 
reviewed in Chapter 5, raw Korean ginseng products can be differentiated using 
metabolomics by characterising features such as species, age and region of origin of the plant 
products. Other herbal products have also been similarly profiled and evaluated 123,132,161,182. 
Metabolomics can also be used to help find new biomarkers for quality control 131. However, 
using metabolomics to validate the final composition and therefore quality of commercial 
products is only starting to be explored 154. Chapter 6 profiled commercially available green 
tea and Korean ginseng products and compared them to standard reference materials (SRM) 
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using PCA. The results found that there were significant compositional differences between 
products and SRM, as well as intra-sample variation. Despite stating that they contained the 
same ingredients, there was dissimilarity in the biochemical profiles of the product tested. 
The implications and causes of this diversity remain to be investigated. The possibility of using 
metabolomics to help develop quality control standards by profiling the complete 
composition of products at all stages of production is another strong area of research124,154,183. 
Limitations and improvements 
There are many limitations within this body of work. The many mass spectrometry techniques 
used each have strengths and weaknesses, and not one of the employ methods gives a 
complete picture on its own. Chapter 2 used a routine LC-MS toxicology screening method in 
positive mode only. The LOQ of this method were developed for therapeutic levels of 
pharmaceuticals only 21. As a targeted screen, novel drug analogues and relevant 
phytochemicals would not be detected. It was these limitations in mind that the rapid, 
untargeted DSA-TOF analysis was explored as an application. However, detailed method 
validation for the DSA-TOF analysis is still required, with the assessment of matrix and ion 
suppression, in-source fragmentation, quantitative capacity, and negative mode analysis 
(only positive mode was used in the current analyses). The DSA-TOF is also capable of direct 
analysis of solid samples rather than the solvent extractions utilised in this research. Chapters 
3 and 4 have shown that this direct analysis methodology is appropriate for analysis of herbal 
medicines, mainly where the form of products such as oils, gels and pastes are more 
challenging for traditional methods. The major limitation for chapter 6 is that the components 
of interest remain unidentified, which is the next step in this research. Similarity, the use GC-
MS for the metabolomics analysis, while helpful for the use of spectra libraries for the future 
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identification of components, does have the limit of requiring derivatisation for thermally 
labile and non-volatile compounds. Future use of both GC-MS and LC-MS based metabolomics 
would give a more comprehensive view of product composition. 
These limitations should not however take away from the novelty of this work.  The 
combination of DNA, multiple MS techniques, on commercially purchased products is current 
the only published investigation of Australian products, giving a clearer insight to the 
character of what are very popular commercial health products. The combination of 
techniques also strengthens the conclusions overall, helping to offset of each method’s 
individual limitations. All methods: DNA testing, LC-MS, direct MS, or GC-MS each raise 
questions about the true content of herbal products. 
 
Conclusion: 
This thesis set out to answer four questions: 
1. What is the occurrence of adulteration/contamination in CAM products available in 
Australia? 
Approximately 50% of the samples tested contained additional plant (31%) and animal DNA 
(2%), animal contaminants (12%), or additional pharmaceuticals (5%) when tested using a 
combined method of targeted LC-MS and DNA barcoding. This occurrence conceivably 




2. What is the compositional diversity /similarity of formulated herbal products? 
There are consistent, significant compositional differences between products and reference 
standards, which means that regardless of having the consistent ingredients, products are 
diverse enough to challenge the idea of ‘pre-approved’ ingredients rather than products. 
3. What is in these herbal products and does the content match the label? 
This study has demonstrated that the label is accurate in only a proportion of CAM products 
and that validating the label requires a multi-tiered and multi-method approach. GC and LC-
MS, DNA testing and also direct MS methods can all be used in combination to give a holistic 
overview of product content and composition. 
4. What is the risk posed to consumers by CAM products? 
The risk to consumers is still undefined; however, many risks have been identified in this work. 
Contaminated and adulterated products, possibly inaccurate labels and products not listed 
with the relevant regulatory bodies could all pose a risk for consumers. As people cannot 
know precisely what they are consuming, the idea that these products are ‘low-risk’ needs to 
be contested. 
There are various future lines of inquiry that can develop from this work. Broadly focusing on 
the topics of composition and safety, further research is needed into the differences in herbal 
products and any relation to differences in toxicity. To enable this research, supporting the 
development of rapid screening and profiling methods would facilitate evaluation of 
compositional diversity. Metabolomics and mass spectrometry can be utilized in all areas of 
this future research as demonstrated in this thesis, complementing other specialities such as 
DNA barcoding. Research collaboration between regulation bodies, industry and academia 
would be of further benefit to ensure the highest quality products. Such research would carry 
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substantial costs, however it is worthy of funding, as this research and thesis has shown that 
the pre-approval of ingredients by Australian regulators does not necessarily generate 
compliant products. Despite the numerous studies undertaken and the different methods 
employed in this research, we still cannot with absolute certainty specify the contents of the 
products tested. It is only through the work presented here and future work that herbal 
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Supplementary Table 9-1: Internal standards used for LC-QTOF analysis at FSSA. 
Compound Concentration (mg/L) 
Olanzapine D8 0.125 
Oxycodone D3 0.050 
Alprazolam D5 0.050 
BFPMP 0.333 
Quetiapine D8 0.125 
Amphetamine D5 0.125 
7-Aminoflunitrazepam D7 0.063 
Diazepam D5 0.150 
Oxazepam D5 0.175 
Methamphetamine D5 0.100 
Atropine D3 0.100 
13C6 Amlodipine 0.097 




Supplementary Table 9-2: Adulterants, contamination, undeclared ingredients, plant and animal families and genera detected in the CAM 
products tested in this study. Samples 78, 186 and 253 are same product but different batches, noted by “1” and “2”. Samples 296 and 307 






Ingredients On Package  Toxicological data DNA Plant DNA Animal Comments 
1 Y Euphausia superba 
   
Nothing detected 
4 N Apium graveolens, Astragalus 
membranaceus, Avena sativa, Barosma 
betulina, Berberis vulgaris, 
Betacarotene, Biotin, Calcium ascorbate 
dihydrate, Calcium citrate, Calcium 
pantothenate, Camellia sinensis, Carica 
papaya, Centella asiatica, 
Cholecalciferol, Choline bitartrate, 
Chromium picolinate, Citrus 
bioflavonoids extract, Copper 
gluconate, Crataegus monogyna, 
Cyanocobalamin, Cynara scolymus, d-
alpha tocopheryl acid succinate, 
Equisetum arvense, Ferrous fumarate, 
Foeniculum vulgare, Folic acid, Ginkgo 
biloba, Inositol, Lycopersicon 
esculentum, Lysine hydrochloride, 
Magnesium oxide-heavy, Manganese 
amino acid chelate, Nicotinamide, 
Panax ginseng, Petroselinum crispum, 
Potassium iodide, Potassium sulfate, 
Pyridoxine hydrochloride, Riboflavin, 
Selenomethionine, Serenoa repens, 
Silybum marianum, Smilax officinalis, 
Caffeine Apiaceae, 
Asteraceae, Araliaceae (includes 
Ginseng), 
Ericales (includes Tea), 
Ixoroideae (includes Coffee), 
Solanoideae, 
Rutaceae (includes Citrus), 
Pooideae (inculde Oats) 











Ingredients On Package  Toxicological data DNA Plant DNA Animal Comments 
Spearmint oil, Thiamine hydrochloride, 
Turnera diffusa, Tyrosine, 
Ubidecarenone, Vaccinium myrtillus, 
Vitis vinifera, Zinc amino acid chelate, 
Zingiber officinale 
6 Y Caralluma adscendens var. fimbriata 
 
Asterids (includes C. fimbriata), 
Cyamopsis tetragonoloba (Guar 
plant), 
Acalypheae 
  T.S. Neg., 
Additional Plant 
DNA,  Contains 
Fillers, Confirmed 
Ingredients 
8 Y Fig dry, Phoenix dactylifera, Senna 
alexandrina extract 
 
Arecaceae (includes P. 
dactylifera), Fabaceae (includes 
S. alexandrina), Ficus (fig), 




hircus, Sus scrofa 
scrofa 





9 N Fish Oil, Food Acids, Gelatin, Glucose, 
Natural Colours, Natural Flavours, 
Sugar, Vitamin E, Water 
   
Nothing detected 
10 Y Alisma ago aquatica, Comus officinalis, 
Dioscorea opposita, Ophiopogon 
japonicus, Paeonia suffruticosa, Poria 
cocos, Rehmannia glutinosa, Schizandra 
chinensis 
 
Paeonia (includes P. 
suffruticosa), PACMAD clade, 
Anthemideae, Apiaceae, 
Pteridium 





15 Y Ulmus rubra 
 
Ulmus, Brassicaceae   T.S. Neg.,  
Additional Plant 
DNA 
22 N Creosote, Citris Unshiu Peel, Gambir, 
Glycyra, Phellodendron  











Ingredients On Package  Toxicological data DNA Plant DNA Animal Comments 
23 N Calcium Carbonate, Chromium 
Polynicotinate, Garcinia cambogia 
extract, Green coffee extract, 
Magnesium Stearate, Microcrystalline 
Cellulose, Moringa oleifera, Potassium 
Citrate, Silicon Dioxide 
Caffeine Amaranthaceae, Apiaceae, 
Poaceae 





40 Y Ascophyllum nodosum, Fucus 
vesiculosus, Iodine 
 




43 Y Angelica archangelica, Carum carvi, 
Chelidonium majus, Glycyra glabra, 
Iberis amara, Matricaria chamomilla, 
Melissa officinalis, Mentha X piperita, 
Silybum marianum 
   
Nothing detected 
44 Y Abrus cantoniensis, Bupleurum 
falcatum, Curcuma longa, Cyperus 
rotundus, Desmodium styracifolium, 
Gardenia florida, Glycyra uralensis, 
Paeonia veitchii, Rheum palmatum, 
Scutellaria baicalensis 
Synephrine 1.1 mg/g Cedrus, Apiaceae (includes B. 
falcatum), Artemisia, Oleaceae, 
Solanoideae, PACMAD clade 





47 N Angelica polymorpha, Atractylodes 
macrocephala, Bupleurum falcatum, 
Citris aurantium, Glycyra uralensis, 
Leonurus sibiricus, Mentha haplocalyx, 
Paeonia lactiflora, Paeonia suffruticosa, 
Poria cocos, Spatholobus suberectus, 
Trichosanthes kirilowii 




50 Y Docosahexaenoic acid, 
Eicosapentaenoic acid 
   
Nothing detected 
51 Y Docosahexaenoic acid, 
Eicosapentaenoic acid, Euphausia 
superba 









Ingredients On Package  Toxicological data DNA Plant DNA Animal Comments 
52 Y d-alpha tocopherol, Euphausia superba, 
Fish Oil - Natural, Glucosamine 
Hydrochloride 
   
Nothing detected 
53 Y Docosahexaenoic acid, 
Eicosapentaenoic acid 
   
Nothing detected 
54 Y Docosahexaenoic acid, 
Eicosapentaenoic acid, Euphausia 
superba 
   
Nothing detected 
55 Y Euphausia superba, Omega- 
triglycerides 
   
Nothing detected 
59 Y Astragalus complanatus, Calcium 
sulfate, Euryale ferox, Nelumbium 
speciosum, Oyster Shell 
 
Nymphaeaceae, Nelumbo, 
Glycyrrhiza, Rutaceae, Paeonia, 
Asterids 





62 N Unknown 
 
Danthonia, Panicoideae, Maleae, 
Plantago, Gynostemma, 
Rutaceae, Papilionoideae 
(including Fabeae, Glycyrrhiza, 
Vigna) 
  T.S. Neg.,  Contains 
Fillers 
66 Y Amorphophallus konjac 
 




68 Y Coffea canephora 
 
BEP clade, Saliceae, Fabeae, 
Apiaceae, Anacardium  





69 N Acerola Fruit Powder, Alfalfa Powder, 
Apple Powder, Ascorbic Acid, 
Astragalus  Extract, Barley  Powder, 
Beta Glucan, Betacarotene, Bilberry 
 
Papilionoideae (inlcuding 
















Ingredients On Package  Toxicological data DNA Plant DNA Animal Comments 
Fresh Fruit Extract, Biotin, Broccoli 
Powder, Burdock  Extract, Calcium 
Carbonate, Calcium Citrate, Calcium 
Pantothenate, Calcium Phosphate, 
Carica papaya, Carica Papaya Powder, 
Carrot  Powder, Chlorella Powder, Citric 
Acid, Citrus Bioflavanoids Extract, Cocoa 
Bean Polyphenol Extract, Colloidal 
Anhydrous Silica, Copper Gluconate, 
Cyanocobalamin, Dandelion  Extract, 
Dibasic Phosphate, Ergocalciferol, 
Flaxseed Powder, Folic Acid, Ginger 
ome Powder, Globe Artichoke Extract, 
Gotu kola Extract, Grapeseed Extract, 
Green Tea Extract, Hawthorne Fruit 
Powder, Inulin, Kelp   Powder, Lecithin, 
Licorice  Powder, Magnesium Citrate, 
Manganese Amino Acid Chelate, Milk 
Thistle Extract, Nicotinamide, Nicotinic 
Acid, Pea Protein Isolate, Picolinate, 
Pineapple Flavour, Pineapple Fruit 
Extract, Pyridoxine Hydrochloride, RS-
Alpha Lipoic Acid, Red Beet Powder, 
Reishi Mushroom Powder, Resveratol, 
Riboflavin, Rice Bran Powder, Rosehip 
Fruit Extract, Rosemary  Extract, 
Selenomethione, Shitake Mushroom 
Powder, Slippery Elm Powder, Spinach  
Powder, Spirulina, Thaumatin, Thiamine 
Hydrochloride, Ubidecarenone, Vanilla 
Flavour, Wheatgrass Powder, Withania 
somnifera  Extract, Wolfberry (Goji) 
Fruit Powder, Zinc Amino Acid Chelate 
















Ingredients On Package  Toxicological data DNA Plant DNA Animal Comments 
70 Y Shark cartilage 
 












71 Y Colostrum powder - bovine 
 
Fabeae, Helianthease, Triticeae, 
Citrus, Glycine (soybean) 
Bos T.S. Neg.,  Contains 
Fillers 
72 N Flavour, Glucose, Goats Milk Poweder, 
Lactose, Natural Colour 
 
Cucurbitaceae, Theobroma, 
Magnolids, Glycine (soybean) 
Capra hircus T.S. Neg.,  Contains 
Fillers 
74 Y Retinyl Acetate, Lutein, Lycopene, 
Betacarotene, Thiamine Nitrate, 
Riboflavin, Nicotinamide, Pyridoxine 
Hydrochloride, Cyanocobalamin, 
Ascorbic Acid, Cholecalciferol, d-alpha-
tocopherol Acetate, Phytomenadione, 
Biotin, Folic Acid, Calcium 
Pantothenate, Calcium Carbonate, 
Calcium Hydrogen Phosphate, 
Potassium Sulfate, Chromic Chloride, 
Copper Sulfate, Potassium Iodide, 
Ferrous Fumarate, Magnesium Oxide, 
Manganese Sulfate, Sodium Selenate, 
Zinc Oxide 
 
Citrus, Apioideae   T.S. Neg.,  
Confirmed 
Ingredients 
77 Y d-alpha Tocopherol, Ubidecarenone, 
Zinc Amino Acid Chelate 
 
Oryza sativa   T.S. Neg.,  Contains 
Fillers 
78_1 Y Selenomethionine, Silybum marianum, 
Taurine 
 Oryza, PACMAD clade, 
Brassicaceae, Asteraceae 
(includes S. marianum) 
 T.S. Neg.,  
Additional Plant 










Ingredients On Package  Toxicological data DNA Plant DNA Animal Comments 
78_2 Y Selenomethionine, Silybum marianum, 
Taurine 
 Asteraceae (includes S. 
marianum) 
Sus scrofa T.S. Neg.,  
Confirmed 
Ingredients 
79 Y Ascorbic Acid, Vaccinium macrocarpon 
 
Rutaceae, Maleae, Poaceae, 
Juglandaceae  




80 Y Citris bioflavonoids extract, 
Tocotrienols complex - palm 
 
Rutaceae (includes Citrus), 
Azadirachta indica 
  T.S. Neg.,  
Additional Plant 
DNA 
81 Y d-alpha-Tocopherol 
   
Nothing detected 





Ulex, Melicytus, Phormium 
tenax, Laurales, Asteraceae 
  T.S. Neg.,  DNA 
from pollen in the 
honey 
84 Y Globe artichoke (Cynara scolymus), St 
Mary's Thistle, Tumeric 
 
Cynara cardunculus var. 
scolymus, Medicago sativa, 
Zingiberales (includes Curcuma), 
Asparagales, Quercus, 
Brassicaceae, Citrus, Triticeae 





86 Y Cordyceps sinensis, Eleutherococcus 
senticosus, Withania somnifera, 
Ganoderma lucidum, Astragalus 
membranaceus, Panax ginseng, Panax 
quinquefolium 
Buclizine 0.2 g/g Astragalus, Morus, Maleae, 
Brassicaceae, Araliaceae 









91 N Burdock, Dandelion, Milk Thistle, 
Nettle, Spirits 
   
Nothing detected 
93 Y Isatis tinctoria, Taraxacum mongolicum, 
Viola yedoensis  











Ingredients On Package  Toxicological data DNA Plant DNA Animal Comments 
94 Y Curcumin phospholipid complex 
 
Papilionoideae   T.S. Neg.  
99 Y Chromic chloride, Cinamomum cassia, 
Coleus forskohlii, Gymnema sylvestre, 
Hydroxycitrate complex 
   
Nothing detected 
105 Y Biotin, Chromium pioclinate, 
Cinnamomum cassia, L-Leucine, 
Manganese amino acid chelate, 
Momordica charantia 
   
Nothing detected 
107 N Gymnema 
   
Nothing detected 
113 Y Cunara scolymus (globe artichoke), 
Silybum marianum (Milk Thistle) seed, 
Taraxacum officinale (Dandelion)  
   
Nothing detected 
116 Y Alisma ago aquatic, Bupleurum 
falcatum, Cornus officinalis, Dioscorea 
opposita, Paconia suffruticosa, Poria 
cocos, Rhemania glutinosa, Schizandra 
chinensis  
   
Nothing detected 
121 Y Achyranthes bidenta, Eucommia 
ulmoides, Gardenia floridia fruit, 
Gastrodia elata tuber, Leonurus 
sibiricus herb, Oyster shell powder, 
Polygonatum multiflorum , Poria cocos 
fruit , Scutellaria baicalensis, Uncaria 
rhyncophylla , Viscum coloratum herb 
 
Asteraceae, Lamiales (includes 





Lonicera, Galium, Boraginaceae, 
Convolvulaceae, Solanum, 
Thermopsis, Prunus, Rosoideae, 
Ulmaceae, Brassicaceae, Avena, 
Triticeae, Zingiberaceae  





124 Y Angelica polymorpha, Carthamus 
tinctorius, Ligusticum wallichii, Paeonia 
laciflora, Prunus persica, Rehmannia 
glutinosa  
 
Paeonia (includes P. laciflora), 
BEP clade, Rutaceae, Apiaceae 
(includes A. polymorpha and L. 
wallichii) 










Ingredients On Package  Toxicological data DNA Plant DNA Animal Comments 
125 Y Arctium lappa, Cynara scolymus, 
Schisandra chinensis, Silybum 
marianum, Taraxacum officinate 
   
Nothing detected 
128 Y Achyranthes bidenta, Angelica 
polymorpha, Bupleurum falcatum, 
Carthamus tinctorious, Citrus 
aurantium, Glycyra uralenses, 
Ligusticum sinense, Paeonia lactiflora, 
Platycodon grandiflorum, Prunus 
persica, Rehmannia glutinosa 
Synephrine 0.32 
mg/g 
Amaranthaceae (includes A. 
bidenta), Apisceae (includes A. 
polymorpha and B. falcatum), 
Paeonia (includes P. laciflora), 
Sapindales (includes C. 
aurantium), Poaceae, 
Polycarpon, Polygonoideae 






134 Y Alisma orientale, Angelica polymorpha, 
Bupleurum falcatum, Clematis 
armandii, Gardenia florida, Gentiana 
scabra, Glycra uralensis, ago asiatica, 
Rehmannia glutinosa, Scutellaria 
baicalensis 
 
Apiaceae (includes A. 
polymorpha), Gentiana, 
Glycyrrhiza, Astragalus 





135 Y Aloe Ferox powder 
 
Calocedrus decurrens   T.S. Neg.,  
Additional Plant 
DNA 
152 Y Urtica dioica  
   
Nothing detected 
158 Y Iodine, Kelp 
   
Nothing detected 
160 N Acai extract, Gelatin 
 
Arecaceae (includes Acai)   T.S. Neg.,  
Confirmed 
Ingredients 
161 Y Trigonella foenum-graecum 
 
Trigonella, Anthemideae, 
Lonicera, Lamioideae, Capsium, 
BEP clade, Allium, Rutaceae, 
Peganum nigellastrum 




162 Y polygonum cuspidatum dry extract, vitis 





167 N Cat's Claw 
 










Ingredients On Package  Toxicological data DNA Plant DNA Animal Comments 
168 N Wormwood (Artemisia) 
 
Triticeae, Phragmites, 
Asteroideae (includes Artemisia) 




177 N Organic Stinging Nettle 
 
Urtica dioica, Pooideae, 
Lamiaceae, Bromus 
  T.S. Neg.,  
Additional Plant 
DNA 
178 N Devil's Claw 
 
Harpagophytum procumbens   T.S. Neg.,  
Confirmed 
Ingredients 
185 Y Ascorbic acid, Sambucus nigra 
   
Nothing detected 
186_1 Y Allium sativum  Glycine Bos T.S. Neg.,  Animal 
Contaminants 
186_2 Y Allium sativum  Glycine  T.S. Neg.  
187 Y Magnesium, Viburnum opulus, Zingiber 
officinale 
 
Oryza, Brassicaceae, Roscoea, 
Zingiberaceae 






198 N Calcium hydrogen phosphate, Cellulose 
fibre, Gelatine, Maltodextrin, 
Processing aids (E,  E), Sheep Placenta 
concentrate 
 
BEP clade (Oryza) Ovis T.S. Neg.,  Contains 
Fillers 
200 Y (under a 
different 
AUST L) 
Bifidobacterium lactis, Lactobacillus 




T.S. Neg.,  
Additional Plant 
DNA 
201 N sorbitol, maltitol, gum base, maltitol 
syrup, vitamins- C E, niacin B, 
pantothenic acid B, B, A, D, B, flavour, 
vegetable gum, colour, food acid, 
humectant  glazing agent, sweetener 









Ingredients On Package  Toxicological data DNA Plant DNA Animal Comments 
202 N Bacopa, BHT, Carnuba Wax, Ginkgo 
biloba, Guarana, Gum Arabic, Gum 
Base, Maltitol, Monniera, Natural 
Flavours, Resinous Glaze, Sorbitol, Soy 
Lecithin, Sucralose, Titanium Dioxide, 
Vinpocetine, Xylitol 
   
Nothing detected 





207 N Ginkgo biloba, Maca, Reishi Mushroom, 






212 N Chamomill, Colocynthis, Dioscorea 
 
Theaceae, Fabaceae   T.S. Neg.,  
Additional Plant 
DNA 
217 Y Achillea millefolium, Arctium lappa, 
Berberis aquifolium, Frangula 
purshiana, Handroanthus heptaphyllus, 
Rhamnus frangula, Rumex crispus, 
Smilax officinalis, Taraxacum officinale, 













218 Y Lecithin, Piper nigrum, Ubidecarenone 
   
Nothing detected 
219 Y Astaxanthin, d-alpha Tocopherol, 
Haematoccocus pluvialis, Linoleic acid, 
Linolenic acid, Linseed oil, Oleic acid 
   
Nothing detected 
220 Y Betacarotene, Retinyl palmitate, 
Thiamine hydrochloride, Riboflavin, 
Nicotinamide, Calcium pantothenate, 
Pyridoxine hydrochloride, Folic acid, 
Cyanocobalamin, Biotin, Ascorbic acid, 
Chlecalciferol, d-alpha-Tococpheryl acid 
succinate, Calcium carbonate, 
Chromium picolinate, Iron, Magnesium, 
Manganese, Potassium, Selenium, Zinc, 
 
BEP clade (Oryza), PACMAD 
clade, Citrus 










Ingredients On Package  Toxicological data DNA Plant DNA Animal Comments 
Glucosamine sulphate, Choline 
bitartrate, Inositol, Citrus bioflavonoids 
extract, Papain,Lecithin powder, 
Enriched soy, Fucus vesiculosus (Kelp)  
extract 
221 Y Aesculus hippocastanum, Ginkgo 
biloba, Ruscus aculeatus, Vaccinium 
myrtillus 
   
Nothing detected 
224 Y Camellia sinensis, Chitosan, Chromic 
chloride, Chromium picolinate, Citris 
aurantium, Fucus vesiculosus, 
Gymnema sylvestre, Pyridoxine 










226 Y Garcinia gummi-gutta, Nicotinamide, 
Pyridoxine hydrochloride, Thiamine 
hydrochloride 
   
Nothing detected 
227 Y Camellia sinensis, Capsicum annuum, 
Chromic chloride, Citris aurantium, 
Garcinia quaesita, Pyridoxine 
hydrochloride, Taurine, Zingiber 
officinale 




228 Y Camellia sinensis, Cocos nucifera, 






229 Y Coffea canephora Caffeine  Oryza, Triticeae, Apocynaceae, 
Platanus orientalis, Solanaceae 











Ingredients On Package  Toxicological data DNA Plant DNA Animal Comments 
230 N Acai berry, Ascorbic acid, Black tea 
powder, Capsicum annuum, Citric acid, 
Elderberry, Flavours, Goji berry, L-
Carnitine, Pomegranate powder, Red 
grape powder, Schisandra berry, Stevia, 
Xylitol 
Caffeine Lythraceae   Expected 
Pharmaceutical 
231 N Acidophilus, Aloe vera, Bertonite Clay, 
Buckthorn, Calcium carbonate, Cape 
aloe, Cascara sagrada, Cayenne Pepper, 
Cirus pectin, Fennel Seed, Flax Seed Oil, 
Gelatin, Ginger, Irvingia gabonesis, 
Licorice, Magnesium stearate, Oat Bran, 
Prune Juice, Pumpkin Seed, Rhubarb, 
Senna 
 
Quercus    T.S. Neg.  
232 Y Hydoxycitrate complex 
 
Musaceae   T.S. Neg.,  
Additional Plant 
DNA 
233 Y Hydroxycitrate complex 
   
Nothing detected 
234 N African Mango Seed Extract, Calcium 
Phosphate, Hypromellose, Magnesium 
Stearate, Purified Water, Silicon Dioxide 
 
Avena   T.S. Neg.,  Contains 
Fillers 
235 Y Premium Garcinia Extract (Garcinia 
quaesita) 
 
Fagaceae   T.S. Neg.,  
Additional Plant 
DNA 
236 N Hydroxy Citric Acid 
 
Oryza   T.S. Neg., Contains 
Fillers 
237 Y Potassium Iodide, Rubus idaeus 
   
Nothing detected 
238 Y Hydroxycitrate complex 
   
Nothing detected 




240 N Chromic chloride, Cinnamomum cassia, 
Coleus forskohlii, Garcinia quaesita, 









Ingredients On Package  Toxicological data DNA Plant DNA Animal Comments 
Gymnema sylvestre, Hydroxycitrate 
complex, Piper nigrum 










243 Y Crataegus pinnatifida, Dioscorea 
opposita, Nelumbium speciosum, Poria 
cocos 








245 N Cinnamon, Ganoderma mushroom, 
Green Tea, Peppermint, Chicory  













246 Y Citrus aurantifolia, Crataegus 
pinnatifida, Hordeum vulgare, Nelumbo 
nucifera, ago asiatica, Poria cocos, 
Rheum officinale, Senna alexandrina, 
Vigna umbellate 
 
Fabaceae (includes S. 
alexandrina) 
Canis lupus 





247 N Raspberry Ketone 
   
Nothing detected 
248 Unknown Alfalfa Extract, Barley Grass Powder, 
Broccoli Powder, Calcium Hydrogen 
Phosphate, Chlorella Powder, Green 
Kale Powder, Green Tea Extract, Kelp 
Extract, Magnesium Stearate, Nori 
















Ingredients On Package  Toxicological data DNA Plant DNA Animal Comments 
Mushroom Powder, Silica Colloidal 
Anhydrous, Spinach Powder, Spirulina, 
Wheat Grass Powder 
253_1 Y Trigonella foenum-graecum  Trigonella, Parietaria, Musaceae, 
Apocynaceae 








286 Y Coleus forskohlii 
 
Theaceae, Ocimeae   Additional Plant 
DNA, Confirmed 
Ingredients 






Apiaceae    Additional Plant 
DNA 
288 Y Coleus forskohlii, Chromium picolinate 
 




289 N Vitamin B, Chromium picolinate, Green 
tea extract, Cha De Bugre powder, 
Guarana seed extract, Caffeine 
anhydrous, Hoodia chinese extract 










Ingredients On Package  Toxicological data DNA Plant DNA Animal Comments 
290 N African mango extract, Green tea 





291 Y Garcinia cambogia, Hydroxycitric acid, 
Chromium chloride 
 
Musaceae   Additional Plant 
DNA 
292 Y Caralluma adscendens var. fimbriata 
extract  
   
Nothing detected 
293 Y Astragalus membranaceous, Crataegus 
pinnatifida, Polygonum multiform, 
Codonopsis pilosula, Atractylodes 
macrocephala, Nelumbium speciosum, 
Pinellia temata, Poria cocos, Alisma ago 
aquatica, Morus alba, Cassia tora, Citrus 
reticulata, Zizyphus jubata 
 
Asteraceae   T.S. Neg.  
294 N Garcinia Cambogia with HCA, Calcium 
phosphate, Hypromellose, 
maltodextrin, Silicon dioxide, 
Magnesium stearate, Purified water 
   
Nothing detected 
295 N Green tea extract (Camelia sinensis), 
Hordenine, N-Methyltyranine, 
Octopamine, Tyramine, Ginger  
(Gingerols), L-tyrosine, Grape seed 
extract, Quercetin, Vitamin C, Vitamin B 
(as pyridoxine), Pantothenic acid, 
Magnesium carbonate 
 
BEP clade, Crotonoideae   T.S. Neg.,  Contains 
Fillers 








Ingredients On Package  Toxicological data DNA Plant DNA Animal Comments 




  Additional 
pharmaceutical 
297 N Garcinia cambogia, potassium, Calcium, 
Chromium  
 
Poaceae   Contains Fillers 




300 N chromium picolinate, cobalamin (vit B), 
thiamine, riboflavin, niacinamide, 
pantothenic acid, pyridoxine HCl, green 
coffee bean,  chlorogenic acid, gardenia 
cambogia,  HCA, raspberry ketones, 
white kidney bean extract, green tea 
extract. 
 
BEP clade (Oryza)   Contains Fillers 
301 Y paullinia cupana extract, citrus 
aurantium extract, zingber officinale 
extract, panax ginseng extract, camellia 
sinensis extract, psyllium husk powder, 
chromium picolinate, potassium iodide, 
pyridoxine hydrochloride, thiamine 
nitrate, riboflavin, cyanocobalamin 




302 N calcium, iodine, chromium 
polynicotinate, sodium, garcinia 
cambogia extract, panax ginseng  
extract, gelatin, magnesium stearate, 
stearic acid 









Ingredients On Package  Toxicological data DNA Plant DNA Animal Comments 
303 N cellulose, gelatin, african mango seed 
powder, silicon dioxide, magnesium 
stearate, water, maltodextrin 
 
Apiaceae   Additional Plant 
DNA 
304 N acacia rigidula P.E., B-
phenylethylamine,,-dimethoxytramine, 
-methyl--pyridinamine, -
cyclohexylethylamine, tyramine, white 
tea, green tea, kuding tea, dextrose, 
caffeine, hordnine, konjac, cissus 






305 Y Camellia sinensis Caffeine Apiaceae   Additional Plant 
DNA, Expected 
Pharmaceutical 
306 N Unknown 
 
Apiaceae   T.S. Neg.  
307 A N Acacia arabica, Argyreia speciose, 
Asparagus adescendens, Asparagus 
racemosus, Capparis aphylla, 
Convolvulus pluricaulis, Curculigo 
orchioides, Emblica officinalis, 
Glycyrrhiza glabra, Ipomoea digitate, 
Tinospora cordifolia, Vitex trifolia, 
Withania somnifera 
 Cycadales, Apocynaceae, 
Anthemideae, Moltkia, 
Convolvulaceae (includes I. 
digitate), Solanum, Cicer, 
Glycyrrhiza, Asparagus, 
Hypoxidaceae (includes C. 
orchioides), Solanoideae 
(includes W. somnifera), 
Ranunculales, Euphorbiaceae, 
Rutaceae, Apocynaceae, 
Asparagoideae (includes A. 
adescendens and A. racemosus) 




307 B N Centella asiatica, Cinnamomum 
zeylanicum, Convolvulus pluricaulis, 
Curcuma longa, Cyperus rotundus, 
Cyperus scariosus, Elettaria 
cardamomum, Embelia ribes, Ghee, 
Glycyrrhiza glabra, Honey, Meua ferrea, 








Ingredients On Package  Toxicological data DNA Plant DNA Animal Comments 
Phyllanthus emblica, Piper longum, 
Santalum album, Sugar, Terminalia 
chebula 
313  Unknown Unknown 
   
Nothing detected 
314 Y Ascorbic acid, Biotin, Calcium 
pantothenate, Calcium hydrogen 
phosphate anhydrous, Cholecalciferol, 
Chromic chloride, Cupric sulfate 
pentahydrate, Cyanocobalamin, d-
alpha-tocopheryl acid succinate, 
Dunaliella salina, Eleutherococcus 
senticosus, Ferous fumerate, Folic acid, 
Inositol, Magnesium oxide-heavy, 
Manganese amino acid chelate, 
Nicotinamide, Potassium iodide, 
Pyridoxine hydrochloride, Riboflavin, 
Selenomethionine, Silybum marianum, 
Thimine nitrate, Zinc amino acid chelate 
   
Nothing detected 
316 Y Ascorbic Acid, Folic Acid, Ferrrous 
Fumerate, Cyanocobalamin 
 
Beta vulgaris   T.S. Neg.  
317 Y Natural vitamin E (d-alpha Tocopherol) 
   
Nothing detected 
319 N Creatine Monohydrate, Dextrose, Peak 
ATP 
 
PACMAD clade, Ocimum, 
Theobroma, Papilionoideae, 
Anacardium 








  T.S. Neg.  
321 Y Camellia sinesis  extract, fallopia 
japonica  extract, standardised to 












Ingredients On Package  Toxicological data DNA Plant DNA Animal Comments 








Acalypheae, Linum, Triticeae, 
Medicago, Tribuloideae 
(includes T. terrestrial) 





323 Y Citrus aurantium fruit, coleus forskohlii, 
paullinia cupana seed, capsicum 
frutescens fruit, zingiber officinate ome, 
camelia sinesis, RS-alpha lipoic aicd, 
levocarnitine, potassium iodide 
Caffeine, Synephrine 
7.4 mg/g 
Platycladus orientalis, Capsicum, 
Glycyrrhiza, Rosaceae, PACMAD 
clade, Theaceae 





324 N Calcium Sulphate 
 




Supplementary Table 9-3: The pharmaceuticals, analogues, and phytochemicals which were 


































































































































































































































































































































































































Zuclopenthixol  C22H25Cl1N2O1S1 
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Supplementary Table 9-4: The standard mix compounds structure and expected detection 
results. The predicted detections are based on previous in-house work on an LC-MS/MS using 
both ESI and APCI ionization (unpublished) and the compounds chemical properties (e.g. 
polarity) given the DSA is a modified APCI source and a literature search.  
Compound Expected to be 










N N + 
Aspirin 
 
N N - 
Brucine 
 
Y Y + 
Caffeine 
 
Y Y + 
Chlorpheniramine 
 
Y Y + 
Codeine 
 















Y Y + 
Digoxin 
 
N N + 
Diphenhydramine 
 
Y Y + 
Ephedrine 
 
Y Y + 
Ibuprofen 
 






Y Y + 
Mianserin 
 
Y Y + 
Paracetamol 
 









Y Y + 
Salicylic acid 
 
N N - 
Sibutramine 
 






Y Y + 
Simvastatin 
 
Possibly N + 
Streptomycin 
 
N N + 
Strychnine 
 
Y Y + 
Tadalafil 
 
Y Y + 
Tamoxifen 
 
Y Y + 
Vardenafil 
 







Y Y + 
Warfarin 
 
Y Y + 
Yohimbine 
 




# Library -------------------------------------------------------------------------------------------------------------- 












# Functions ---------------------------------------------------------------------------------------------------------- 
 
#Functions for error values 
mass_error<-function(a,e) { 
  a-e 
}#a= measured accurate mass, e=exact mass 
ppm_error<-function(a,e) { 
  ((a-e)/e)*(10^6) 
} #a= measured accurate mass, e=exact mass 
 
#this works for individual data frames 
Matching_function<-function(RD,tolerance){ 
  SI<-data.table( 
    Compound =SF$Compound, 
    Formula = SF$Formula, 
    Mass = as.numeric(SF$m.z), 
    Start = as.numeric(SF$m.z) - tolerance, 
    End = as.numeric(SF$m.z) + tolerance, 
    Rel.Ab = SF$Abundance, 
166 
 
    key= c("Start", "End")) 
  foverlaps((data.table(RD)), SI)%>% 
    subset(select = c(Sample,Compound, Formula, Mass, Start, End, Rel.Ab, m.z, Intensity)) 
} 
 
#same as above but with ppm error 
Matching_function_ppm<-function(RD,tolerance){ 
  SI<-data.table( 
    Compound =SF$Compound, 
    Formula = SF$Formula, 
    Mass = as.numeric(SF$m.z), 
    Start = as.numeric(SF$m.z) - tolerance, 
    End = as.numeric(SF$m.z) + tolerance, 
    Rel.Ab = SF$Abundance, 
    key= c("Start", "End"))   
  R<-foverlaps((data.table(RD)), SI)%>%  
    subset(select = c(Sample,Compound, Formula, Mass, Rel.Ab, m.z, Intensity)) 
  Error<-as.data.frame(mass_error(R$m.z,R$Mass)) 
  ppm<-as.data.frame(ppm_error(R$m.z,R$Mass)) 
  cbind.data.frame(R,Error,ppm) 
} 
 
# Required Information ------------------------------------------------------------------------------------------- 
 
###Information import for data analysis### 
#See Isotope pattern code on how to compile a data.frame of isotopic patterns 
data(adducts) 
data(isotopes) 
#Write own list using http://www.envipat.eawag.ch/index.php or the enviPat package. 
#import standard substance istopic patterns as SF (standard formula). 
Standard_Patterns <- read.csv("C:/Users/ellyc/Documents/PhD/R/Standard_Centroid.csv", 
                              stringsAsFactors = FALSE) 
SF<-Standard_Patterns 




#import raw data as CSV files with columns:  
#m.z, start, end (duplicates of the m.z columns) Abundance or Intensity and sample name. 
#see Isotope matching code for examples 
 
# Sample data import section ----------------------------------------------------------------------------------- 
 
#The code below works as an import loop for the triplicate samples 
dataR<-Sys.glob("C:/Users/ellyc/Documents/PhD/CAM samples/Category D/CAM_296 
B/SP_*.csv") %>% 
  lapply(read.csv,stringsAsFactors=FALSE) 
 
for(i in 1:length(dataR)) { 
  assign(paste0("Raw.", i), dataR[[i]]) 
} 
 
# Analysis section -------------------------------------------------------------------------------------------------- 
 
#single working line for DSA-ToF searching function 

























# Processed Data Import ----------------------------------------------------------------------------------------- 
#code for dealing with processed data: 
#import loop for the triplicate samples 
dataP<-Sys.glob( 
  "C:/Users/ellyc/Documents/PhD/CAM samples/Category D/CAM_296 B/Raw_*.xlsx")%>% 
  lapply(read.xlsx2,sheetIndex=1,stringsAsFactors=FALSE) 
 
for(i in 1:length(dataP)) { 








specify_decimal <- function(x, k) trimws(format(round(x, k), nsmall=k)) 
for(i in 1:length(Processed.1)){ 
  Processed.1$Sample =Processed.1[1,2] 















for(i in 1:length(Processed.2)){ 
  Processed.2$Sample = Processed.2[1,2] 













for(i in 1:length(Processed.3)){ 
  Processed.3$Sample =Processed.3[1,2] 

















# Comparing tripicates -------------------------------------------------------------------------------------------- 
P4<-inner_join(P1,P2, by="Mass") 
P5<-full_join(P4,P3, by="Mass") 
P6<-P5 %>% distinct(Mass, .keep_all=TRUE) 






D/CAM_296 B/CAM_296 B.xlsx")) 
 
##END DATA CLEAN UP## 
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Supplementary Table 9-5: Data from the original study 184 with the addition of the DSA ID. ‘Further investigation needed’ is noted when a wide 
variety of putative compounds have been identified, but adulteration or contamination cannot be confirmed. Samples 78, 186 and 253 include 







Ingredients on package  Toxicological data DSA ID (error) DNA plant DNA animal Comments 
4 N Apium graveolens, 
Astragalus 
membranaceus, Avena 

















tocopheryl acid succinate, 
Equisetum arvense, 
Ferrous fumarate, 
Caffeine Phenylephrine/ Synephrine 
(5.15 ppm) 
Niacinamide (4.88 ppm) 
Pyridoxine (7.84 ppm) 
Pantothenic acid (7.87 
ppm) 
Epinephrine (7.97 ppm) 
Thiamine (5.64 ppm) 










Pooideae (inculde Oats) 











Ingredients on package  Toxicological data DSA ID (error) DNA plant DNA animal Comments 
Foeniculum vulgare, Folic 














Serenoa repens, Silybum 
marianum, Smilax 
officinalis, Spearmint oil, 
Thiamine hydrochloride, 
Turnera diffusa, Tyrosine, 
Ubidecarenone, 
Vaccinium myrtillus, Vitis 
vinifera, Zinc amino acid 
chelate, Zingiber 
officinale 
6 Y Caralluma adscendens 
var. fimbriata 
 

























Ingredients on package  Toxicological data DSA ID (error) DNA plant DNA animal Comments 




Trigonelline (4.34 ppm) 
Pyridoxine (3.53 ppm) 
Arecaceae (includes P. 
dactylifera), Fabaceae 
(includes S. 












9 N Fish Oil, Food Acids, 
Gelatin, Glucose, Natural 
Colours, Natural Flavours, 
Sugar, Vitamin E, Water 
 
Scopoletin (3.80 ppm) 
Ferulic acid (7.42 ppm) 
Alpha thujone (3.48 ppm) 














Trigonelline (3.86 ppm) 
Pyridoxine (10 ppm) 
Phenylephrine/ Synephrine 
(3.17 ppm) 
Thiamine (5.01 ppm) 












15 Y Ulmus rubra 
 
Pyridoxine (3.92 ppm) 
Cantharidin (9.13 ppm) 
Curcumin (7.31 ppm)  
Ginkgolide A (6.35 ppm) 






22 N Creosote, Citris Unshiu 















Ingredients on package  Toxicological data DSA ID (error) DNA plant DNA animal Comments 
23 N Calcium Carbonate, 
Chromium Polynicotinate, 
Garcinia cambogia 





Citrate, Silicon Dioxide 
Caffeine Caffeine (3.59 ppm) Amaranthaceae, 
Apiaceae, Poaceae 





40 Y Ascophyllum nodosum, 
Fucus vesiculosus, Iodine 
 




43 Y Angelica archangelica, 
Carum carvi, Chelidonium 
majus, Glycyra glabra, 
Iberis amara, Matricaria 
chamomilla, Melissa 




Trigonelline (5.55 ppm) 
Kaempferol (7.55 ppm) 




44 Y Abrus cantoniensis, 
Bupleurum falcatum, 
Curcuma longa, Cyperus 
rotundus, Desmodium 
styracifolium, Gardenia 
florida, Glycyra uralensis, 





Wogonin (6.78 ppm) 
Tyramine (8.45 ppm) 
Synephrine# 
Cedrus, Apiaceae 
















Ingredients on package  Toxicological data DSA ID (error) DNA plant DNA animal Comments 














Amisulpride (4.77 ppm) Panax, Ericale, 
Dalbergieae 



















52 Y d-alpha tocopherol, 
Euphausia superba, Fish 


























59 Y Astragalus complanatus, 
Calcium sulfate, Euryale 
ferox, Nelumbium 
speciosum, Oyster Shell 
 
Pyridoxine (7.84 ppm) 
Phenylephrine/ Synephrine 
(10.31 ppm) 


















Ingredients on package  Toxicological data DSA ID (error) DNA plant DNA animal Comments 




62 N Unknown 
 
Salicylic acid (4.32 ppm) 
Cinnaminc acid (4.86 ppm) 
Ferulic acid (5.54 ppm) 
Catharidin (7.27 ppm) 
Norketamine (9.67 ppm) 












66 Y Amorphophallus konjac 
 
 Araceae (includes A. 
konjac) 




68 Y Coffea canephora 
 
Pantothenic Acid (2.88 
ppm) 
BEP clade, Saliceae, 
Fabeae, Apiaceae, 
Anacardium  
Bos T.S. Neg., Animal 
Contaminants, 
Contains Fillers 
69 N Acerola Fruit Powder, 
Alfalfa Powder, Apple 
Powder, Ascorbic Acid, 
Astragalus  Extract, Barley  
Powder, Beta Glucan, 
Betacarotene, Bilberry 
Fresh Fruit Extract, Biotin, 








































Ingredients on package  Toxicological data DSA ID (error) DNA plant DNA animal Comments 
Powder, Carrot  Powder, 
Chlorella Powder, Citric 
Acid, Citrus Bioflavanoids 
Extract, Cocoa Bean 
Polyphenol Extract, 
Colloidal Anhydrous 
Silica, Copper Gluconate, 
Cyanocobalamin, 
Dandelion  Extract, 
Dibasic Phosphate, 
Ergocalciferol, Flaxseed 
Powder, Folic Acid, 
Ginger ome Powder, 
Globe Artichoke Extract, 
Gotu kola Extract, 
Grapeseed Extract, Green 
Tea Extract, Hawthorne 
Fruit Powder, Inulin, Kelp   
Powder, Lecithin, Licorice  
Powder, Magnesium 
Citrate, Manganese 
Amino Acid Chelate, Milk 
Thistle Extract, 
Nicotinamide, Nicotinic 
Acid, Pea Protein Isolate, 
Picolinate, Pineapple 
Flavour, Pineapple Fruit 
Extract, Pyridoxine 
Hydrochloride, RS-Alpha 











Ingredients on package  Toxicological data DSA ID (error) DNA plant DNA animal Comments 
Rice Bran Powder, 
Rosehip Fruit Extract, 
Rosemary  Extract, 
Selenomethione, Shitake 
Mushroom Powder, 
Slippery Elm Powder, 






somnifera  Extract, 
Wolfberry (Goji) Fruit 
Powder, Zinc  Amino Acid 
Chelate 
70 Y Shark cartilage 
 













71 Y Colostrum powder - 
bovine 
 
 Fabeae, Helianthease, 
Triticeae, Citrus, 
Glycine (soybean) 









Ingredients on package  Toxicological data DSA ID (error) DNA plant DNA animal Comments 















Chromic Chloride, Copper 




Sodium Selenate, Zinc 
Oxide 
 
Niacinamide (2.17ppm) Citrus, Apioideae   Confirmed 
Ingredients 
77 Y d-alpha Tocopherol, 
Ubidecarenone, Zinc 








78_1 Y Selenomethionine, 
Silybum marianum, 
Taurine 
 Kaempferol (4.53ppm)  
Quercetin (0.99 ppm) 
Oryza, PACMAD clade, 
Brassicaceae, 
Asteraceae (includes S. 
marianum) 












Ingredients on package  Toxicological data DSA ID (error) DNA plant DNA animal Comments 
78_2 Y Selenomethionine, 
Silybum marianum, 
Taurine 
 Kaempferol (2.44ppm) 
Quercetin (1.54ppm) 
Taurine (1.42 ppm) 
Asteraceae (includes S. 
marianum) 
Sus scrofa T.S. Neg., 
Confirmed 
Ingredients 
80 Y Citris bioflavonoids 
extract, Tocotrienols 
complex - palm 
 
 Rutaceae (includes 
Citrus), Azadirachta 
indica 
  T.S. Neg., 
Additional Plant 
DNA 


















  T.S. Neg. (DNA 
from pollen in 
the honey) 
84 Y Globe artichoke (Cynara 
scolymus), St Mary's 
Thistle, Tumeric 
 
Quercetin (0.77 ppm), 
Kaemperol (5.69 ppm) 






















 Astragalus, Morus, 
Maleae, Brassicaceae, 
Araliaceae 











Ingredients on package  Toxicological data DSA ID (error) DNA plant DNA animal Comments 








91 N Burdock, Dandelion, Milk 







93 Y Isatis tinctoria, 
Taraxacum mongolicum, 







94 Y Curcumin phospholipid 
complex 
 
 Papilionoideae   T.S. Neg. 









121 Y Achyranthes bidenta, 
Eucommia ulmoides, 
Gardenia floridia fruit, 
Gastrodia elata tuber, 
Leonurus sibiricus herb, 
Oyster shell powder, 
Polygonatum multiflorum 
, Poria cocos fruit , 
Scutellaria baicalensis, 
Uncaria rhyncophylla , 
Viscum coloratum herb 
 
Wogonin (2.34 ppm) 
Trigonelline (7 ppm) 
Cinnamic Acid (6.48 ppm) 



















Triticeae, Zingiberaceae  















Ingredients on package  Toxicological data DSA ID (error) DNA plant DNA animal Comments 
124 Y Angelica polymorpha, 
Carthamus tinctorius, 
Ligusticum wallichii, 




 Paeonia (includes P. 
laciflora), BEP clade, 
Rutaceae, Apiaceae 
(includes A. 
polymorpha and L. 
wallichii) 
  T.S. Neg., 
Confirmed 
Ingredients 














(includes A. bidenta), 
Apisceae (includes A. 
polymorpha and B. 
falcatum), Paeonia 
(includes P. laciflora), 













  T.S. Neg., 
Confirmed 
Ingredients 
186_1 Y Allium sativum   Glycine Bos T.S. Neg., Animal 
Contaminants 
186_2 Y Allium sativum   Glycine  T.S. Neg. 
217 Y Achillea millefolium, 



























Ingredients on package  Toxicological data DSA ID (error) DNA plant DNA animal Comments 
Zanthoxylum clava-
herculis 
218 Y Lecithin, Piper nigrum, 
Ubidecarenone 
 




221 Y Aesculus hippocastanum, 




















Riboflavin (1.59 ppm) 






225 Y Coffea canephora Caffeine 50.59 
mg/g 
Pyridoxine (0.78 ppm) 









Niacinamide (7.59 ppm) 
Pyridoxine (6.27 ppm) 
Thaimine# 




227 Y Camellia sinensis, 
Capsicum annuum, 








Pyridoxine (4.90 ppm)  
Gallic acid (3.90 ppm) 
Methcathinone (8.33 ppm) 
















Ingredients on package  Toxicological data DSA ID (error) DNA plant DNA animal Comments 







Kaempferol (7.31 ppm) 




229 Y Coffea canephora Caffeine 0.43 
mg/g 
 Pantothenic Acid#  Oryza, Triticeae, 
Apocynaceae, Platanus 
orientalis, Solanaceae 




230 N Acai berry, Ascorbic acid, 
Black tea powder, 
Capsicum annuum, Citric 
acid, Elderberry, Flavours, 
Goji berry, L-Carnitine, 
Pomegranate powder, 
Red grape powder, 




L-Theanine (1.90 ppm) 
Caffeine (4.27 ppm) 
Quercetin (6.16 ppm) 
Lythraceae   Expected 
Pharmaceutical 
231 N Acidophilus, Aloe vera, 
Bertonite Clay, 
Buckthorn, Calcium 
carbonate, Cape aloe, 
Cascara sagrada, Cayenne 
Pepper, Cirus pectin, 
Fennel Seed, Flax Seed 
Oil, Gelatin, Ginger, 
Irvingia gabonesis, 
Licorice, Magnesium 
stearate, Oat Bran, Prune 
Juice, Pumpkin Seed, 
Rhubarb, Senna 
 
 Quercus    T.S. Neg. 
232 Y Hydoxycitrate complex 
 










Ingredients on package  Toxicological data DSA ID (error) DNA plant DNA animal Comments 










Purified Water, Silicon 
Dioxide 
 
Pyridoxine (5.68 ppm) 
Ephedrine (10.64 ppm) 
Avena   Contains Fillers 
235 Y Premium Garcinia Extract 
(Garcinia quaesita) 
 
 Fagaceae   Additional Plant 
DNA 
236 N Hydroxy Citric Acid 
 
 Oryza   Contains Fillers 
237 Y Potassium Iodide, Rubus 
idaeus 
 
Pyridoxine (7.05 ppm), 














Pyridoxine (1.57 ppm) 
Quinic acid (9.84 ppm) 
Kaempferol (1.74 ppm) 
Epicatechin (3.55 ppm) 
Quercetin (2.31 ppm) 
Epigallocatechin (5.43 ppm) 







240 N Chromic chloride, 
Cinnamomum cassia, 
Coleus forskohlii, Garcinia 
quaesita, Gymnema 
sylvestre, Hydroxycitrate 
complex, Piper nigrum 
 









Pyridoxine (9.80 ppm) 












Ingredients on package  Toxicological data DSA ID (error) DNA plant DNA animal Comments 
Caffeine (7.53 ppm) 
Panthothenic Acid# 
Levetiracetam (1.36 ppm) 












Alpha-Thujone (11.67 ppm) 
Gallic Acid (2.34 ppm)  
Caffeine (6.84 ppm) 
Kaemperol (2.09 ppm) 
Epicatechin (4.24 ppm) 
Quercetin (3.74 ppm) 








Trigonelline (3.14 ppm) 






Prednisolone (5.45 ppm) 
Levetiracetam (5.26 ppm) 







245 N Cinnamon, Ganoderma 
mushroom, Green Tea, 
Peppermint, Chicory  
Caffeine 3.63 
mg/g 
Caffeine (4.27 ppm) 
Kaempferol (4.88 ppm) 
Quercetin (3.19 ppm) 
















246 Y Citrus aurantifolia, 
Crataegus pinnatifida, 
Hordeum vulgare, 
Nelumbo nucifera, ago 
 
Kaempferol (8.01 ppm) 
Isorhamnetin (3.99 ppm) 
Ginkgolide A (11.49 ppm)  
Fabaceae (includes S. 
alexandrina) 
Canis lupus 












Ingredients on package  Toxicological data DSA ID (error) DNA plant DNA animal Comments 
asiatica, Poria cocos, 
Rheum officinale, Senna 
alexandrina, Vigna 
umbellate 





248 Unknown Alfalfa Extract, Barley 
Grass Powder, Broccoli 
Powder, Calcium 
Hydrogen Phosphate, 
Chlorella Powder, Green 
Kale Powder, Green Tea 
Extract, Kelp Extract, 
Magnesium Stearate, 
Nori Powder, Pea Protein, 
Povidone, Shitake 
Mushroom Powder, Silica 
Colloidal Anhydrous, 
Spinach Powder, 




Kaempferol (3.72 ppm) 
Epicatechin (4.47 ppm) 








253_1 Y Trigonella foenum-
graecum 
 Trigonelline (5.07 ppm) 













253_2 Y Trigonella foenum-
graecum 
 Trigonelline (4.34 ppm) 
Phenylephrine/ Synephrine 
(4.56 ppm) 













Ingredients on package  Toxicological data DSA ID (error) DNA plant DNA animal Comments 
286 Y Coleus forskohlii 
 
Forskolin (5.67 ppm) 
Azatadine (4.47 ppm) 
Theaceae, Ocimeae   Additional Plant 
DNA, Confirmed 
Ingredients 







 Apiaceae    Additional Plant 
DNA 
288 Y Coleus forskohlii, 
Chromium picolinate 
 
Forskolin (3.65 ppm) 
Flupentixol (1.53 ppm) 




289 N Vitamin B, Chromium 
picolinate, Green tea 
extract, Cha De Bugre 




Caffeine 141 mg/g Pyridoxine (1.37 ppm) 
Caffeine (4.95 ppm) 
Kaempferol (0.12 ppm) 
Quercetin (5.61 ppm) 





290 N African mango extract, 













 Musaceae   Additional Plant 
DNA 
292 Y Caralluma adscendens 
















Ingredients on package  Toxicological data DSA ID (error) DNA plant DNA animal Comments 








Pinellia temata, Poria 
cocos, Alisma ago 
aquatica, Morus alba, 




Trigonelline (4.11 ppm) 
Phenylephrine/ Synephrine 
(3.77 ppm) 
Asteraceae   Further 
investigation 
needed 
294 N Garcinia Cambogia with 














Ginger  (Gingerols), L-
tyrosine, Grape seed 
extract, Quercetin, 





Pyridoxine (0.78 ppm) 
Theobromine/ Theophylline 
(4.05 ppm) 
Adrenaline (2.72 ppm)  
Caffeine (7.35 ppm) 














Ingredients on package  Toxicological data DSA ID (error) DNA plant DNA animal Comments 
296 A       T.S. Neg.  
296 B    Paracetamol (10.52 ppm) 
Chlorpheniramine (3.51 
ppm) 
Ephedrine (7.02 ppm) 









 Poaceae   Contains Fillers 
298 N Green coffee bean extract  Caffeine 0.06 
mg/g 
Caffeine (8.71 ppm) Ericales, Fabaceae, 
Apiaceae 




300 N chromium picolinate, 
cobalamin (vit B), 
thiamine, riboflavin, 
niacinamide, pantothenic 
acid, pyridoxine HCl, 
green coffee bean,  
chlorogenic acid, 
gardenia cambogia,  HCA, 
raspberry ketones, white 
kidney bean extract, 
green tea extract. 
 
Pyridoxine (3.92 ppm) 
Pantothenic Acid (6.81 
ppm) 
Trigonelline (6.04 ppm) 
Niacinamide (2.98 ppm) 
Riboflavin (1.24 ppm) 
Kaempferol (3.14 ppm) 
Quercetin (3.41 ppm) 
BEP clade (Oryza)   Contains Fillers, 
Confirmed 
Ingredients  
301 Y paullinia cupana extract, 
citrus aurantium extract, 
zingber officinale extract, 
panax ginseng extract, 
camellia sinensis extract, 
Caffeine 27.43 
mg/g 
Caffeine (5.64 ppm) 
Pyridoxine (1.76 ppm) 
Epicatechin (6.64 ppm) 
Plantago, Brassicaceae, 
Rosids 











Ingredients on package  Toxicological data DSA ID (error) DNA plant DNA animal Comments 







302 N calcium, iodine, 
chromium polynicotinate, 
sodium, garcinia 
cambogia extract, panax 







303 N cellulose, gelatin, african 





Caffeine (8.37 ppm) Apiaceae   Additional Plant 
DNA 
305 Y Camellia sinensis Caffeine 2.85 
mg/g 
Caffeine (2.73 ppm) 
Epicatechin (4.47 ppm) 
Epigallocatchin (9.63 ppm) 
Epigallocatechin Gallate 
(6.75 ppm) 
Kaempferol (2.79 ppm) 
L-theanine (1.71 ppm) 
Quercetin (3.19 ppm) 
Scopoletin (6.91 ppm)  





313  Unknown Unknown 
 
Niacinamide (2.44 ppm) 
Pantothenic Acid (6.51 
ppm) 
Riboflavin (1.95 ppm) 











Ingredients on package  Toxicological data DSA ID (error) DNA plant DNA animal Comments 








319 N Creatine Monohydrate, 
Dextrose, Peak ATP 
 













  T.S. Neg. 
321 Y Camellia sinesis  extract, 
fallopia japonica  extract, 
standardised to contain 
resveratrol   
Caffeine Caffeine (5.98 ppm) 












Ephedrine (7.22 ppm) 
Trigonelline (7 ppm) 
Promazine or Promethazine 
(5.62 ppm) 












323 Y Citrus aurantium fruit, 
coleus forskohlii, paullinia 
cupana seed, capsicum 
frutescens fruit, zingiber 
officinate ome, camelia 






Ephedrine (8.43 ppm) 
Phenylephrine/ 
Synephrine (1.78 ppm) 













324 N Calcium Sulphate 
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